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The objective of this study was to evaluate the status of the counterfeit pharmaceuticals 
in Jordan. Four types of pharmaceuticals Lipitor (Atorvastatin-calcium), Concor 
(bisoprolol fumarate), Co-Diovan (Valsartan, hydrochlorothiazide) and Plavix 
(clopidogrel) were subjected to physical and chemical analysis. 173 samples of these 
four medicines were collected from the three most populated cities in the country, 
namely Amman, the capital of Jordan, Zarqa and Irbid. A sample of confiscated 
counterfeited medicines was obtained from the health authorities and tested utilising the 
HPLC and dissolution testing, in order to validate the reliability of the testing 
procedures. Samples were then tested using High Performance Liquid Chromatography 
(HPLC) and dissolution tests in order to assess the quality of these samples. 
Results of both chemical and physical analyses revealed that all samples were found to 
fall within the specification limits of United States Pharmacopoeia (USP) and no 
evidence was found of any counterfeit drug products in the samples examined. 
Since this study found no indication of a drug counterfeiting problem in Jordan, the 
researcher has concluded that there seemed to be two contributing factors to this result: 
first, the very effective legislative campaigns conducted by the health authorities’ in 
Jordan against counterfeit trade through new public health and pharmacy law which has 
been launched in 2008. Second, the rigorous tough enforcement measures conducted  
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Public health and the quality of medicine are both considered to be a main concern for 
health organisations worldwide and health authorities within countries. 
During the last decade, counterfeit pharmaceuticals have generated global concern about 
their efficacy and the threat they cause to the health of the public. 
During the same period, a new form of unregulated pharmaceutical trade gave the chance 
for imitated brand pharmaceuticals to appear in the market place. Consumers may use such 
products with their full belief that they are using the original brand while in fact they 
constitute a form of counterfeit pharmaceuticals. 
Background information about the country of Jordan is provided in Appendix (A). 
 
1.2 Health System and Counterfeit Pharmaceuticals Situation in Jordan 
Following sections present detailed information about health system and counterfeit 
pharmaceutical elements in Jordan. 
 
1.2.1 Pharmaceutical Distribution System in Jordan 
For imported medicines, the JFDA along with the Ministry of Health (MOH) are 
responsible for the registration and authorisation of the medicine, which enters the country 
through a long process that includes obtaining pedigree papers from the pharmaceutical 
manufacturer, and a certificate of pharmaceutical product (CPP) from the country of origin. 
Trained inspectors are being sent to these manufacturers to make sure that they are in 
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compliance with the good manufacturing practices. Finally, health authorities are also 
required to evaluate the price of the medicine in order to be sure the price is compatible 
with price levels in the region. 
Once the medicine is approved and registered for use then the wholesaler can import it 
from the supplier. A random sample of every batch is usually selected to be subjected to 
JFDA laboratory analysis. The objective of this analysis is to assure that all shipment 
batches are free of problems related to safety of the medicine, which is considered as a 
proof of complying with specifications. Once positive results of drug samples are obtained 
the wholesaler is allowed to distribute the medicine directly to the pharmacies or public and 
private hospitals. 
 
 In Jordan, the drugstore is any pharmaceutical institution engaging in importing, 
purchasing, selling, storing or distributing of drugs to pharmacies (Royal Decree 2001).  
 Import of drugs to the country is normally conducted by a drugstore, which is acting as an 
agent for the originator. 
 
Once the medicine is approved and registered for use then the agent can import it from the 
supplier. Usually for each product, there is only one agent who is legally allowed to import 
the product after obtaining all required registration and authorisation requirements of the 
JFDA. This might explain the fact that parallel trade does not exist in Jordan because only 
the authorized wholesalers (agents) can import the product and other routes of importing 
are considered illegal, and shipment is subjected to confiscation and fines. 
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There are twelve districts in Jordan; each district has its own inspectors. The inspector is 
usually any pharmacist authorized for inspection by health regulatory authorities. 
Inspectors assume the responsibility of securing the proper compliance of public and 
private pharmacies with standards, such as expiry dates or illegal drug sale and drug recall 
activities. Another level of inspection is done by inspectors from the headquarters of JFDA 
in Amman who are assigned to perform unexpected visits to any district in the country. 
 
There are two types of inspections usually conducted by JFDA: 
 Routine inspections, which take the form of unannounced visits to all public and private 
pharmacies. 
 Inspections following a complaint or a suspected behavior. This inspection is usually 
done by health inspectors accompanied with police officers especially if the complaint 
is related to a serious incident.  
 
1.2.2 Counterfeit Trade Routes in Jordan 
According to health authorities, counterfeit pharmaceuticals used to enter into the country 
through the following routes: 
 Smuggling through the borders without passing customs by avoiding the regular 
passage of entry. 
 Importing through regular borders depending on the high quality of packaging, which 
can deceive the customs authorities. 
5 
 
 Another source of counterfeiting is not through importation.  Counterfeiters do 
sometimes manufacture their products locally without authorisation.   
It seems that drug regulatory authorities acted and corrected the problem that involved 
these pharmaceuticals. For example, authorities have acted decisively by closing ten 
pharmacies in 2006 and sixty-one pharmacies in the year 2007 for selling counterfeit 
products (Sabag 2008).  
Recently, new legislation was enacted to increase penalties for counterfeit pharmaceutical 
traders, and counterfeit drugs were defined for the first time, as detailed in Appendix (C). 
Article number 65 stated that: 
If the person convicted by buying or selling or exporting counterfeit medicine to the 
kingdom,  he will spend a period not less than 3 years and not more than  5 years in prison 
with hard work, or the convicted individual will pay  a fine not less than JD 1000, and not 
more JD 5000, or both penalties. In some serious circumstances, the fine will be twice as 
much as the price of the confiscated counterfeit drug (JFDA 2008). 
 
1.2.3Status of Counterfeit Pharmaceuticals in Jordan 
In Jordan, the health authorities reported many cases of confiscated counterfeited drugs in 
the last several years (Zyiadat 2009), the majority of them are drugs classified as life saving 
medications. In the last several months, cases of confiscated counterfeit drugs have been 
reported by JFDA (Jordan Food and Drug Administration) and several pharmacies were 
closed for dealing with the counterfeit drugs trade. Since there has been no formal research 
done to investigate this problem in the country, this study’s main goal is to evaluate the 
nature and magnitude of the counterfeit problem in Jordan. If results indicate the presence 
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of a significant counterfeit problem, this research will help health authorities and law 
enforcement agencies in their fight against counterfeit drugs. 
 
The JFDA estimated the value of smuggled and counterfeit medicines seized in Jordan 
during the year 2007 was around JD 10 million, equaling 2% of the volume of the general 
consumption of imported medications, which stood at JD 191 million in the same year. 
Another source, the head of Jordan Pharmacists Association (JPA) reported that a value of 
about JD 12 million was confiscated in 2007.  This phenomenon has increased to the point 
where the JFDA has closed down 56 pharmacies for periods not exceeding one month in 
the year 2007, compared to 10 in 2006, and only one pharmacy in 2004, for selling 
smuggled and counterfeit drugs (Halteh 2008). 
 
A daily local newspaper addressed the problem of counterfeiting in Jordan, which reported 
the closing down of 180 pharmacies after seizing counterfeit medications. The General 
Manager for JFDA said that they have confiscated medications worth approximately JD 17 
million (Halteh 2008). 
 
In June 2009, a workshop conducted by the JFDA was held near the Dead Sea to inform the 
media about the situation regarding counterfeit medicines and other issues related to 




It has been reported that the chief inspector at JFDA has announced that 33 pharmacies 
have been closed between January and June for different illegal practices; among these five 
were closed for dealing with counterfeit pharmaceuticals. 
 
It has been reported also that a decline in the number of cases regarding this issue was 
noticed, due to the implementation of new public health laws, which applies more severe 
penalties than before (Zyiadat 2009).  
 
1.3 Regional Counterfeit Situation 
The following section presents the counterfeit situation in some neighboring countries: 
 
1.3.1 In Saudi Arabia,   Arab Consumer and Brand Protection Forum was held in Jeddah 
on May 9, 2009 and  legal bodies agreed to step up legal actions to protect intellectual 
property; the emphasis was in combating counterfeit medicine since the kingdom is 
affected by this trade. One of the participants who was a director for a pharmaceutical 
manufacturer said that 30-40% of the medicine in the market is counterfeited and legal 
action should be considered to stop this trend.   The president of the Jordanian Judicial 
Council and the head of Cassation Court mentioned in the same forum that Jordan has been 
struggling for years to protect brand names through its judiciary system, and recently they 
enacted more than 30 laws to combat piracy and establishing an ongoing training 
programme for judges and judiciary employees to comply with national and international 




1.3.2 In United Arab Emirates, Emirates is considered to have a very important location 
as a trade route specifically Dubai, which has a strategic location on the gulf between Asia, 
Europe and Africa. Dubai has been considered the place where one third of all counterfeit 
medicines confiscated in Europe in 2006 passed through. Smugglers make use of the fact 
that a huge amount of goods is usually moving through Dubai free trade zones. In these free 
trade zones, goods are normally passed through without tariffs and with a minimal 
regulatory oversight. Free trade zones allow the counterfeiters to avoid being rigorously 
inspected   (Bogdanich 2007). 
 
Authorities announced that they have seized a large amount of counterfeit medicines from 
Euro Gulf's warehouses, which were located inside the free trade zone in Dubai. 
The investigation revealed that the route of a complex supply chain of counterfeit drugs 
came from China through Hong Kong, the UAE, Britain and the Bahamas and finally to the 
Internet pharmacy whose customers believed that they were buying from Canada.  This 
Investigation shows that this illegal trade follows complex, sophisticated and hard to trace 
routes (Walt 2007).  
 
1.3.3 In Iraq, another neighboring country to Jordan, the situation was deteriorating since 
the invasion of Iraq in 2003. There is always a lack of the most important medication and a 
need to find it and all kind of medicines are in a severe shortage especially antibiotics and 
life saving medication such as anti diabetes medicines, medicine for cardiovascular diseases 
and cancer medications which create the need to find these medications regardless of the 
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source. This has proven to be a great opportunity to the unauthorised medication to enter 
the country especially with the existence of open borders. It has been reported that 97% of 
the medicine in Iraq now comes from unknown origins especially with the absence of the 
regulatory authority and the fear of health inspectors of being assassinated if they report 
any incident of counterfeiting (Mason and Ali 2005).  
 
Since the opening of the borders, there has been a wide spread of counterfeit and 
substandard pharmaceuticals in Iraq.  Before the invasion of Iraq there were two authorized 
pharmaceutical manufacturers in the country, but after the war many unlicensed 
pharmaceutical manufacturers have spread which led to a lack of good manufacturing 
practice (GMP), and unlicensed drugs street vendors  (Mason and Ali 2005). 
 
1.3.4 In Lebanon, The Ministry of Health launched a public awareness campaign to fight 
the counterfeit trade in the country. In 2004, reports by Lebanon’s parliamentary health 
committee estimated that as much as 35% of the drugs sold in the country are counterfeit. 
The health ministry indicated that the ranges of drugs that have been counterfeited include 
common painkillers such as panadol, antidepressant such as xanax, and the impotence drug, 
which is highly, counterfeited Viagra (Ghosn 2008).  
Lebanon lacks any specific laws regarding counterfeit medicine, but the Health Ministry in 
collaboration with activists within the industry has launched a number of campaigns aimed 
at raising public awareness, including a high profile media campaign conducted in 2006 




1.3.5 In Syria, is another neighboring country with Jordan the problem of counterfeit 
medicines is also a big concern for the authorities in Syria. It is estimated that 20% of the 
counterfeit medicine that is available in the country is an imitation of locally produced 
medicines, while 80% is counterfeit for imported medicines (Morei 2009).  
 
1.4WHO Historical Involvement in Counterfeit Pharmaceuticals 
Concern for quality of pharmaceuticals in international trade started since the establishment 
of the World Health Organisation (WHO) in 1948.  In 1951, the (WHO) Executive Board 
adopted resolution EB7.R79, which asked for consideration of the advantage of a more 
unifying method for drug control worldwide (Martijn 2003).  
The first appearance of counterfeit medicines in international trade was realised as а 
problem at the WHO Conference of Experts on Rational Drug Use in Nairobi, Kenya, in 
1985 (WHO 2005).   
Since then, public awareness of the problem of counterfeit drugs has gradually grown 
(WHO 2005). Both government authorities and manufacturers have engaged in different 
levels of efforts aimed at attacking the problem.  
In 1988, the world health assembly adopted resolution WHA41.16 that aimed at initiating 
programs for the prevention and detection of the export, import and smuggling of 
counterfeit and substandard pharmaceuticals (WHO 2005). 
In April 1992, WHO and the International Federation of Pharmaceutical Manufacturers and 
Associations (IFPMA), in Geneva, organised the first international gathering on counterfeit 
drugs.                
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In 1995, using financial support from the government of Japan, WHO launched a project on 
counterfeit drugs, to help member states in the assessment of the counterfeit problem by the 
development of measures to combat counterfeiting (WHO 1999). 
Guidelines for developing measures to combat counterfeit drugs have been prepared within 
the framework of the world health organisation (WHO). Their purpose was to assist 
member states of WHO in efforts to prevent the infiltration of national drug distribution 
channels by counterfeit drugs.  
These guidelines were aimed mainly at government, national drug regulatory authorities, 
national law enforcement agencies and the judiciary. It was   hoped that they might also be 
useful to pharmaceutical industry, drug importers, distributors, relevant professional 
associations and consumers. 
In the same year, WHO developed a program on drug counterfeiting where 30 experts from 
drug regulatory authorities, international non-government organisation (NGOs), and other 
involved institutions participated. The aim of such an activity was to have a forum whose 
main responsibility is to assess the status of the problem and possible solutions. It also 
aimed at the establishment of a network designed to strengthen the measures against 
counterfeiting and the development of a manual to assist governments in the 
implementation of these actions (WHO 1999).  
In November 1997, an international workshop on drug counterfeiting was held. One of its 
recommendations was that WHO continues its role as an observer for the purpose of 
collecting and analysing reports and monitoring the situation in the member states.  
In 2004, regulatory authorities of more than 60 countries met in Madrid for a two-day 
satellite conference on counterfeit medicines. This conference was organised by WHO in 
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collaboration with member states regulatory authorities. Strategies and international 
collaboration on combating counterfeit drugs was discussed (WHO 2006 a).  
In recent years, some countries have participated in efforts to fight the counterfeiting of 
drugs through passing legislations that are more specific, strengthening existing 
legislations, and establishing agreements for cooperation.  
For example, the regulatory authority in Nigeria (NAFDAC) has restricted imports from 30 
foreign companies. Nigeria usually maintains inspectors in exporting countries to ensure 
that drugs exported to Nigeria meet the required standards. 
Another example was when the ministry of public health In Peru launched information 
campaigns calling on Peruvian citizens to purchase medicines only at registered pharmacies 
(WHO 2006). 
As a result, WHO started to receive reports related to counterfeit drugs from some of its 
member states on а voluntary basis.  However, with all these activities the definitions of 
counterfeit medicine was not yet unified among delegates of different countries.  
 
1.5 Definition of Counterfeit Drug 
 In reality, the reason that has aggravated the problem of counterfeiting is that each country 
defines counterfeit medicine differently, so what is considered counterfeit in one country 
might not be considered counterfeit in another. This fact indicates the necessity of having a 
global understanding of the counterfeit problem and a unified definition of what exactly 




There is no unified methodology of defining a counterfeit drug at a global level.  The 
definition, which is usually used in practice, was based on the laws and regulations of 
different countries, which created a conceptual problem for parties who engage in the 
collection of data and the implementation of measures to combat counterfeit drugs.  
Most available definitions have concentrated on the magnitude and characteristics of the 
counterfeit drug.  
Appendix (B) shows different definitions for counterfeit drugs as defined in different 
countries, (WHO 2007 a).  
In this thesis, the WHO definition of counterfeit pharmaceutical issued as an official 
definition. The Jordanian statement of counterfeit definition is also used. 
The (WHO) and the International Federation of Pharmaceutical Manufacturers Association 
established in 1992 a working definition of counterfeit drugs, which is still in use by the 
WHO today. 
Following is the WHO definition: 
“As one which is deliberately and fraudulently mislabeled with respect to identity and / 
 or source. Counterfeiting can apply to both branded and generic products, may include 
products with the correct ingredients or with wrong ingredients, without active ingredients, 
with insufficient active ingredients or with fake packaging." (WHO 2007 a). 
In Jordan, in the year 2008, new legislation was enacted to specifically define a counterfeit 
drug. It stated that the medicine is considered counterfeit when: 
 The medicine is manufactured in an unauthorised place or manufactured by a 
manufacturer other than the original one or without written permission of it. 
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 The medicine does not contain an active ingredient or a different amount of active 
ingredient than stated in the original label. 
 The medicine has a counterfeit trademark or a counterfeit label  
 The medicine has a fraudulent country of origin either inside or outside packaging 
(Public health and pharmacy law 2008). 
In all definitions, counterfeiting is realised when the drug does not have active ingredients 
or contains active ingredients less than the genuine ones. Usually counterfeiters reduce the 
amount of active ingredients to the minimum just to get positive results in the identification 
test.  
A drug is also considered counterfeited if it contains harmful ingredients, or has active 
ingredients but manufactured by an unauthorised manufacturer. The rule is that, even if 
only the packaging is fake, these drugs remain dangerous because they were produced 
without following a proper quality control system, as manufacturing guides indicate the 
present work. 
The WHO definition has three characteristics that the drug should have in order to be 
classified as counterfeit.  These characteristics focus on the fact that a counterfeit is a 
forgery, a copy or imitation, is made without authority or right, and with an intention to 
deceive or defraud, by introducing the copy or imitated drug as the original or genuine one.  
The definition of counterfeit used in Jordan conforms to the WHO definition, and in 
addition to that, it places a great emphasis on complying with trademark law, and 
intellectual property rights.   
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For the purpose of this research, the WHO definition of counterfeit drug is going to be 
used.  
In discussing counterfeit drugs there are many terms used and can be sometimes considered 
as counterfeit or facilitate the movement of the counterfeit drugs and these terms are: 
substandard, diverted, parallel trade. Following are the definitions of these terms: 
 
1.5.1Substandard Medicine:  According to the WHO, substandard medicines are genuine 
drugs, which do not meet the quality specifications designed for them and are usually 
produced by legitimate manufacturers (Caudron et al. 2008).   
The United Stated Pharmacopoeia defines substandard product as “legally branded or 
generic products, but one that does not meet international standards for quality, purity, 
strength or packaging” (Caudron et al. 2008). 
Substandard medicines are often made without complying with good manufacturing 
practices (GMP), or do not conform to the pharmacopoeial standards set for them (U.S. 
Pharmacopoeia 2004). 
Good Manufacturing Practices (GMP) are required standards set forth by the authorities in 
order to ensure that the products are always produced at the required quality levels. GMP 
are considered as general guidelines that should be followed during the engagement with 
pharmaceuticals starting from the raw materials, through the processing, packaging, 
labeling and finally when the final product reaches the consumers (WHO 2003 c).   
Substandard pharmaceuticals normally contain less active ingredients than what the label 
claims.    
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Therefore, poor compliance with Good Manufacturing Practice (GMP) can lead to 
substandard drugs; this may be accidental, or because of insufficient resources, lack of 
specific expertise, or lack of appropriate manufacturing infrastructure (Caudron et al. 
2008). 
Substandard medicines can have serious public health consequences such as contamination, 
which can cause fatal toxicity, (Caudron et al. 2008).  Lack of active ingredients can lead to 
ineffective treatment and prolonged illness or death. Finally, under dosing of active 
ingredient may have the additional risk of causing drug resistance. 
 
1.5.2 Drug Diversion: This occurs when pharmaceutical products do not follow the proper 
distribution chain from the manufacturer to the patient. Instead, diverted pharmaceuticals 
pass through a complex series of transactions before being dispensed to the patient. 
 Drug diversion is considered a threat to the public because some of these drugs may have 
passed their expiration date, some may not be stored under proper conditions, or some may 
have false labels.  
The problem with drug diversion is that it may facilitate the counterfeit medicine to enter 
the distribution chain and appear legitimate. 
 
1.5.3 Parallel Trade occurs when products protected by patent, trademark or copyright are 
first distributed into one market then re-imported into a second market without the 
authorisation of the original manufacturer, the owner  of the intellectual property rights 
(IPRs).  The main motive for Parallel trade is usually to realise a high profit rate due to the 
different price levels (Arfwedson   2004).  
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This process of parallel trading includes repackaging and relabeling medicines, which may 
create opportunity for counterfeiters to enter their products into the distribution chain. 
Those who support parallel trade maintain that parallel trade can lower prices, especially 
for consumers and government, who are looking for ways of reducing health expenditure. 
As is the case in European Union countries, due to different national prices between 
European Member states, parallel trade occurs by purchasing medicine from countries with 
low prices, importing them into countries where pharmaceuticals were usually sold at 
higher price and thus making profit utilising the deferential of prices  (Arfwedson  2004).  
It has been found in many investigations in prior studies that the longer the chain of 
distribution the more chance of introducing counterfeit or substandard pharmaceuticals and 
this could have the affect of not knowing the source of the drugs in time of recalls 
(Catizone 2006).  
 
1.6 Historical Development of Counterfeit Trade 
The first appearance of counterfeit medicines was seen as a progression of substandard 
medication, which was usually produced by legitimate manufacturers but with insufficient, 
or without active ingredients.  
This problem was further aggravated due to the advances of high technology, which made 
it possible for counterfeiters to imitate drugs in order to generate more profits. 
In the past, the counterfeited pharmaceuticals that are being targeted are usually differing in 
type between developed and developing countries. In developed countries the counterfeiters 
targeted life style medications such as Viagra and hormones, but now they have expanded 
their business to include all types of medicine especially life saving ones, and the newer 
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brand names and the highly priced medications such as anti-cancer, and anti-HIV 
medicines (WHO 2003 a). 
In the developing countries, counterfeiters also targeted generic drugs that are used in 
widespread diseases, life threatening diseases such as tuberculoses HIV/AIDS, higher 
priced medications such as anti-cancer, and growth hormones, and medical consumables 
such as gauze, and other medical appliances. 
Counterfeit drugs were responsible for more than 100.000 deaths each year in South East 
Asia as a result of taking fake drugs (Stevens 2006). Half of the drugs sold in South East 
Asia for malaria are counterfeited and do not contain the required level of active 
ingredients; as a result, drug resistance to anti-malarials has been generated. 
In general, with the spread of this phenomenon more and more medications are being 
targeted by the counterfeiters. 
Counterfeiters have made use of improved quality of the packaging due to the use of high 
technology, which makes it hard for consumers and the law enforcement authorities to 
differentiate between legitimate and counterfeited medicines. 
It is a well-known fact that, the presence of these counterfeited medications affects the 
credibility of health care system, which normally suffers when the counterfeit medicines 
get into the legitimate distribution channels. 








1. Products without active ingredients.  
2. Products with incorrect quantities of active ingredients. 
3. Products with wrong ingredients.  
4. Products with correct quantities of active ingredients but with fake packaging. 
5.  Products with high levels of impurities and contaminants (WHO 2007 a). 
In 2002, the World Health Organisation estimated that as much as 5% of the medicine 
consumed in developed countries are counterfeit, compared to more than 10% in the 
developing countries.  In 2006, it was reported that approximately 10% of the medicines 
consumed in developed countries were counterfeit, while 25% was reported to be 
counterfeit in developing countries. In some countries, the figure reaches more than 50% 
(WHO 2006 a). 
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 
reported a 32% increase in the number of countries which are experiencing counterfeiting 
incidents from 67 countries in 2004 to 89 countries in 2005 (Wertheimer and Norris  2009).  
 It has been reported that the sales of counterfeit medicines globally is approximately 
between US$ 37 - 40 billion for 2005. The Center for Medicines in the Public Interest, in 
the United States, predicts that counterfeiting sales will become US$75 billion globally in 
2010, an increase of more than 90% from 2005 (WHO 2006a).  
Basically, all features of drugs were subjected to counterfeiting: active ingredients, dosage 
form, package inserts, packaging, manufacturer's name, batch number, expiry date and 
documentation relating to quality controls (German Pharma Health Fund 2004).  
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Despite the fact that this trade is expanding, authorities in different governments and 
pharmaceutical industries show reluctance to report cases of counterfeit fearing that the 
public loses confidence in medicine and might stop taking their medications, in addition to 
the fear that publicity might harm the sale of medicine and reputation of the industry.  
Despite the efficient reporting system WHO maintains, it received only 84 reports of 
counterfeit drugs between 1999 and 2002 (Cockburn et al. 2005).  
 
1.7 Factors Affecting the Growth of Counterfeit Pharmaceuticals 
 
The problem of counterfeit medicines is well recognised globally, in both developed and 
developing countries. An important factor that contributes to the spread of this trade is the 
lack of a clear definition for counterfeit product. Many countries have their own definition 
of what is considered counterfeit, which creates a problem in defining the term counterfeit 
product, therefore what is considered a counterfeit in one country might not be considered 
counterfeit in another. This indicates how significant it is to have a universal definition to 
be applied in all countries (Kelesidis et al. 2007).  
It addition to the above major factor there are some other factors: 
1- The financial gain acquired by counterfeiters, since these pharmaceuticals are    
produced without any manufacturing standards to comply with and away from any 
quality control systems. These are normally expensive due to the requirement for 
applying Good Manufacturing Practices (GMP) which are usually required from 
legitimate pharmaceutical manufacturers.  
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2- The high price of genuine drugs and insufficient medical health insurance, especially in 
developing countries, has led consumers to look for lower price medications that are 
possibly counterfeited. This explains the fact that poorer segments of societies are most 
affected by counterfeiting. 
3- Weakness or absence of drug regulatory authorities or lack of drug legislation and   
appropriate enforcement. 
4- The use of  high technology to produce high quality packaging to replicate legitimate 
drugs making it hard to distinguish between the real and counterfeit medicine.  
5- The non-traditional ways of buying drugs through the internet and mail delivery, 
especially in developed countries, which offer a huge opportunity for counterfeiters to 
sell their products.   
6- Corruption in certain legal systems, especially in developing countries, where actions 
are not decisive when a counterfeit drug is discovered. 
7- Government actions to encourage people to look for cheaper medicine because prices of 
legitimate drugs are higher due to higher levels of taxes and tariffs. 
8- The pharmaceutical industry keeps the data of fake medicine secret for Security and fear 
that the publicity might harm the sales of their brand name drugs (Cockburn 2005). 
9- Complex transactions involving many intermediaries such as having more than one 
wholesaler, which prolong supply chain system thus increasing the opportunity of 





The production of counterfeit drugs occurs in many countries but China and India are 
considered the main producers for these formulated drugs and the bulk active ingredients, 
which are used all over the world for the production of counterfeit drugs (Khan and Ghilzai 
2007). 
The counterfeit threat is considered as a problem because: 
 The inability of traditional drug distribution channels to identify counterfeit. 
 Non-traditional drug distribution systems such as (the internet and postage systems) are 
growing without proper regulation to avoid counterfeit drugs. 
 Evidence is normally destroyed when the drug is ingested or injected, and if the patient 
does not get better, few people suspect that the drug is counterfeited. 
 
1.8 The Use of Counterfeit Medicines can be Harmful in Many Ways: 
1- The use of toxic chemicals causes injury or death, as in the case of using antifreeze, 
which resulted in 89 deaths in Haiti in 1995(WHO 2006a). 
2- The use of insufficient amount of active ingredients prevents the medicine from being 
effective. Counterfeit medicine is responsible for increasing drug resistance among very 
dangerous infectious diseases such as: malaria, HIV/AIDS and tuberculosis (TB) 
because these medications contain incorrect active  ingredients which causes some 
strains of  bacteria and viruses to mutate, multiply and spread which results in serious 
illness and death as a result of improper treatment ( Morris and Stevens 2006).  
3- The use of counterfeit drugs could cause adverse effects, especially if they contain toxic 
materials, or pathogenic contaminants. Pathogens have been found in case of 
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counterfeited drugs where gentamicin eye drops was contaminated with gentamicin-
resistant pseudomonas aeruginosa which led to severe eye infections (Newton et.al 
2006a).).222   
There are numerous cases of counterfeit medicine but the following are some              
examples: 
 Paracetamol syrup prepared by using glycerol which was contaminated with diethylene 
glycol (a toxic chemical used as an anti-freeze) 89 people died in Haiti in 1995(WHO 
2006 a). 
 During the meningitis epidemic in Niger, vaccines were contaminated, 2500 people died 
after being vaccinated by contaminated vaccine (WHO 2006a). 
 It is estimated that in 2001 in China alone, counterfeit drugs caused the death of 
192,000 patients, and the Chinese government closed 1300 factories involved in the 
production of counterfeit drugs (Newton et al. 2006 b).  
 WHO estimates that 200,000 of the one million malaria deaths a year would have been 










1.9 What has been done to address the Problem?            
There have always been international efforts to combat the problem of counterfeit 
medicine. In 2005 the (WHO) established the “Rapid Alert System” (RAS) a mechanism 
serving as a rapid alert for member states and partner organisations who engage in 
combating counterfeit medicines in the Western Pacific Region .  
When counterfeit medicine is detected in the region and reported through the RAS, relevant 
authorities are notified immediately and relevant actions are taken (Wertheimer and Norris 
2009).   
 In 2006, The World Health Organisation (WHO) has created an International Medical 
Products Anti-Counterfeiting Task Force (IMPACT) to try to coordinate different efforts to 
control this illegal trade around the world. Their major concern is to increase the public 
awareness of counterfeit drugs and to encourage the consumers to report any suspected 
counterfeit products (Khan and Ghilzai 2007). 
The United States Food and Drug Administration (FDA) also created an internal Task 
Force in order to control and prevent counterfeit drugs from reaching consumers. 
In the United Kingdom the Medicines and Healthcare Products Regulatory Agency 
(MHRA) has established the Defective Medicines Report Center (DMRC) to receive and 
assess complaints and reports of suspected defects and coordinates necessary actions 
resulting from these reports. As a consequence of such a warning, drugs are to be 
withdrawn from the marketplace and an alert is issued.  This alert is classified on a scale 
from one to four depending on the seriousness of the defect and its impact on public health. 
Class 1 is the most critical, such as serious mislabeling, microbial contamination or 
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incorrect ingredients, and requires immediate recall, and Class 4 is the least critical and 
advises caution in use of the drug (MHRA 2006). 
The European Parliament and the Council of Europe are considering new regulations 
(Andrew2007).   
Companies have created the pharmaceutical security institute (PSI) and developed global 
security strategies to ensure public safety and product integrity (IFPMA 2006).  
Therefore, in order to address the problem of counterfeiting, many aspects of cooperation 
and coordination among different stakeholders are needed: law enforcement agencies, drug 
regulatory, customs and the pharmaceutical industry. Specifically some actions can be 
taken: 
1- To increase level of awareness of health professionals and the public so that they are 
able to discover, evaluate and report any incident of counterfeit in a timely fashion. 
2- To enhance governments and other groups working for social and health concerns 
capabilities to educate the general public by utilising information campaigns, 
advertisements, and any other means of mass communication. 
3- To encourage patients to report any deficiency in improvement of their health status or 
any adverse reaction observed by them to their physicians or health workers 
immediately (Dahiya 2008). 
4- To encourage pharmacists to exert maximum care when choosing their suppliers.  
5- It should be required that, governments should find ways to reduce the tax burden on 
medicines so the prices  of genuine drugs can become affordable which should curb the 
prevalence of counterfeiters. 
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6- To enhance regulation by creating judiciary systems that are highly informed of the 
complications of counterfeiting issues and their impact on public health. 
 
1.9.1 Pharmaceutical Measures     
In fact, the pharmaceutical industry has utilised many technologies to control this problem. 
The objective of using these technologies was to make counterfeiting more difficult and 
more expensive. 
In an attempt to protect against the counterfeit trade, the pharmaceutical industry has been 
trying to implement many measures. One of them was the use of authentication 
technologies such as the use of invisible ink, chemical taggants, tamper-resistant packaging 
tape and chemical markers.  
The use of holograms is of particular significance.  Holograms are a unique pattern that 
could be obtained through the interaction of laser beams that is produced by the 
manufacturer. The ability of holograms to provide effective protection lies in the 
continuous innovation in inventing holographic techniques (Deisingh 2005).  
Lancaster (2008) has this to say about the advantages of holograms: 
“ Holograms are widely used now in different formats such as holograms to protect 
branded bottled products against counterfeiting and holograms for blister packaging, and 
holographic induction cap seals, polyester-based tamper evident labels used to seal 
packages, holographic hot stamping foil where the hologram is fused to the host surface by 
heat and pressure.  Advantages to the use of security holograms include the following: they 
are difficult to counterfeit, they are recognizable to the consumer, and they are relatively 
cheap. ”  
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Despite all of that counterfeiters have manage to produce low quality holograms in a way to 
deceive the authorities and the patients. It has been reported that, all the techniques above 
were imitated by the counterfeiters in a very short period. It has been noticed that within six 
months from using these techniques the counterfeiters were able to imitate them. 
Another one was the use of serial numbers ID known as serialization, which can be applied 
to product packaging.  This method, also called traces and track technology, uses different 
technologies including barcodes and Radio Frequency Identification (RFID) tags. 
 Barcodes technology is an identification method that allows each pack to have a unique 
serial number, which can be traced to insure the authentication of the product as it moves 
through the distribution channel (Rudolf 2004).  
Radio frequency Identification (RFID) method uses a radio frequency chip that stores all 
the critical data  related to a product in the form of electronic product code (EPC) or 
(electronic pedigree) which document the movement of  the containers of  the drug through 
the supply chain. It involves radio frequency chips applied to all medicine and 
computerised readers to trace their movement (Kontnik 2006 a).  
“Drug pedigree is the statement that identifies prior sales, purchase or trade of the drug 
including the date of the transaction and the names and addresses of all parties to the 
transaction.” (Kontnik 2006 a) 
 Chips can be hidden in a place that cannot be seen, and then a chip reader can trace the 
information on the chip as the product moves through the distribution chain. (RFID) is 
considered an effective method as an electronic tracking technology, with a cost varying 
from a few pence to several pounds depending on specifications such as data capacity, 




There are some problems related to the use of this technique, particularly when used with 
biotech medicine.  The problem arises when radio frequency waves are absorbed by the 
proteins in the product causing degradation, which compromises the safety and 
effectiveness of the product (Crooker 2009). 
Another problem associated with the use of radio waves is that these waves can be 
absorbed by the liquids and reflected by metals that make up most biotech products. This 
could make reading the tags attached to biotech products more difficult.  
Another point worth mentioning here is that this technique is costly since it needs special 
equipment and a secure tracking system throughout the distribution chain to validate the 
RFID tags.  
 
All of these problems made the implementation of this technique inefficient until 
pharmaceutical companies invent solutions to overcome such problems before full and safe 
implementation (Kontnik 2006 b).  
In conclusion, there is no simple solution to eliminate counterfeit medicines, and the 
problem cannot be solved individually. The problem has reached a global level and needs a 
global approach that is why it is very important to rely on strong regulation and 







1.10 Intellectual Property and Counterfeiting 
The relationship between Intellectual Property and counterfeit is that counterfeiting is only 
one aspect of a larger problem of IP right infringement. While it is true that an increasing 
awareness of the importance of IP is spreading worldwide, therefore IP protection has 
became an important element of international trade agreements and many trade issues were 
linked to such protections. Consequently, the problem of counterfeit drugs has been 
approached internationally through multilateral trade negotiations. 
As a result, many countries, which have no anti IP regulations, were forced to develop 
regulations in order to avoid trade sanctions.  Thus, many third world countries adopted 
legislation to guarantee IP laws and enforcement. But due to the severe lack of resources to 
enforce these laws, IP protections become laws without effective enforcement a situation 
that aggravates the problem rather than solving it.  However, the fact remains that strong IP 
Rights and enforcement mechanisms are vital in the fight against counterfeit drugs. 
The pharmaceutical industry depends on IP rights to help in the recovery of substantial 
amounts of investment in the creation and marketing of new drugs. 
Therefore, it is important that, the acquisition and proper enforcement of IP rights should be 
maintained in order to support companies in their effort to protect themselves and their 
consumers from fake drugs. 
To combat counterfeiting, trademarks and patent rights provide the most relevant IP 
protection. 
Trademark laws are usually designed to protect against unauthorised use of a product’s 
name or appearance in a way that is confusing due to similarity to a product that is used by 
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a legitimate producer.  Therefore, counterfeiting occurs when a counterfeited drug appears 
to be manufactured by the authentic manufacturer even upon careful inspection. 
Trademark owners can initiate a judicial claim against anyone who makes, sells or 
distributes counterfeit medicines that infringe their marks. 
Patent laws provide protection against unauthorised manufacturing, use or sale of an 
authentic drug product or medical process. 
In many countries around the world, IP violations can also be subjected to criminal 
prosecution in terms of fines or imprisonment. In many countries, IP rights can also be 
intersecting with customs laws, which create new mechanisms to fight counterfeiting 
(Falrbalrn et al. 2007). 
In 1998, Jordan initiated a TRIPS implementation reform that aims at placing Jordan in 
compliance with the world trade organisation legislation. 
TRIPS regulations (Agreement on Trade-Related Aspects of Intellectual Property Rights) 
included an agreement related to the law and policy of patent, copyrights, and trademark. 
 
1.11 Statement of the Problem 
This investigation focuses on evaluating the nature and magnitude of the counterfeit 
problem in Jordan, so that a reliable estimate of the presence of counterfeit drug in the 
Jordanian market in four life- saving medications can be obtained.  
This statement of the problem is formulated in such a way that aims at specifically 
providing an answer to the following research question: 
Does a counterfeit drug problem exist in Jordan? If it does exist, to what extent does it 




1.12 Aims and Objectives of the Study 
This investigation aims to obtain a reliable and unbiased estimate of the presence of 
counterfeit drugs in four life saving medications that are commonly used within the 
Jordanian market.  
 At this point it seems to be relevant to mention that, this study aimed at uncovering the 
status of counterfeit drug in Jordan, therefore it is not directing to any specific drug.   
To reach this end, the researcher intended to collect samples of the following medicines and 
analyse them to identify their active components as well as the level of compliance to Good 
Manufacturing Practices (GMP). 
The study examined the problem of counterfeit pharmaceuticals by considering all aspects 
of pharmaceutical compliance including labeling, content, distribution, quality and 
regulation.    
1.13 Specific Research Objectives 
 Following are the specific objectives of this research: 
1. To evaluate the current state of counterfeiting of sampled medicines. 
2. To assess the current state of counterfeiting regulations in Jordan, and emphasize 
different approaches to fight this trade: 
a- To suggest total collaboration between responsible parties such as; Jordan 
Food and Drug Administration (JFDA), drug stores, the police and the 
customs, to combat the counterfeiting problem. 
b- To highlight efforts providing professional training for personnel of drug 
regulatory authorities, police, customs and judiciary on how to identify 
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counterfeit drugs, and the risk involved for the public by using counterfeit 
drug. 
c- To ensure the adoption of strong anti- counterfeiting laws and regulations to 
fight counterfeit medications.  
1.14 Essential Pharmaceuticals 
It has been reported by the World Health Organisation (WHO) that in developing countries, 
counterfeit pharmaceuticals often involves essential drugs that are used for life threatening 
diseases such as the sample of pharmaceuticals in this study (Aka e.al. 2005).  WHO has 
defined essential medicines as: 
” those drugs that satisfy the health care needs of the majority of the population, they 
should therefore be available at all times in adequate amounts and in appropriate dosage 
forms, at a price the community can afford.”(WHO 2007 a). 
 Each country has usually maintained its own list of essential medicines.  This list 
constitutes the minimum level of medicines needed for basic health requirements for 
priority conditions based on estimated future requirements. The list is usually viewed as an 
important action, because it is considered as the basis of national drug policy and 
governments refer strictly to the WHO requirements when making decisions of such a type 
(WHO 2007 b).   
In this study, the reason behind selecting these samples of life saving medications as 
samples for this study was that these pharmaceuticals have been targeted by counterfeiters 
in the past due to their high prices and high demand, which made these products attractive 
targets to counterfeiters, who benefit from the sale of large amounts of products in a short 
period of time. They are considered very popular due to their well-known brand names.  
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At the international level, the four pharmaceuticals were considered among the 200 best 
selling medications worldwide in the year 2008 (Humphreys 2010).  Based on total sales   
in 2008, Lipitor was classified as the number one highest selling drug with sales amounting 
to $13,375 million while Plavix was ranked the second best selling medicine worldwide 
with total sales of $9,455 million in 2008.  Co-Diovan was ranked six in the list with sales 
of $5,740 million, and Concor ranked 171 on the list with sales of $638 million in the same 
year. 
At the local level, these four pharmaceuticals were identified as the four highest selling 
pharmaceuticals each within its group according to International Market Statistics (IMS), 
which is an international market surveying group operating in Jordan in the area of sales 
screening (IMS 2010).  
Following are some basic information about the selected medicines: 
- Lipitor (atorvastatin) belongs to a group of drugs known as statins.  Statins include 
Zocor (simvastatin), Lescol ( fluvastatin), and other pharmaceuticals as listed in table 
 (1-1) Statins reduce total cholesterol as well as LDL cholesterol in blood by preventing the 
production of cholesterol in the liver by blocking HMG- CoA reductase, the enzyme that 
produces cholesterol.  LDL cholesterol is known as the "bad" cholesterol that is primarily 
responsible for the development of coronary artery disease. Therefore reducing LDL 
cholesterol levels stops progression and may even reverse coronary artery disease. 
Atorvastatin also reduces the concentration of triglycerides in the blood and raises the 





Table (1.1): Statin Group Sales in Jordan (IMS 2010). 
 
 
As shown in table 1-1 Lipitor was ranked number one selling drug in Jordan from the group 
of Statin pharmaceuticals. As shown, 980,000 units of Lipitor were sold in the year 2009 
from the total sales of 3,699,000 units for all medicines in the group.  This means that 
Lipitor market share was 25.2%.  
It a well known fact that atorvastatin is rapidly absorbed after oral administration,  
with maximum plasma concentration of 1–2 hours. The absolute bioavailability of the drug 
is approximately 14%; however, the systemic availability for HMG-CoA reductase activity 
is approximately 30%. Administration of atorvastatin with food produces a 25% reduction 
This item has been removed due to third party copyright. The unabridged version of the thesis can be viewed at 
the Lanchester Library, Coventry University. 
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in rate of absorption and a 9% reduction in extent of absorption, although food does not 
affect the plasma LDL-C-lowering efficacy of atorvastatin. Evening dose administration  
is known to reduce the rate of absorption and extent of absorption by 30% each. However, 
time of administration does not affect the plasma LDL-C lowering efficacy of atorvastatin. 
Atorvastatin is highly protein bound (≥98%). 
The most common adverse side effects are raised liver enzymes and muscle problems. 
(Appleby and Sternberg 2002). 
- Plavix (clopidogrel) is an anti-platelet agent (thienopyridine class) which is used to 
prevent blood clots in the coronary artery, and used for the prevention of thrombosis after 
placement of intracoronary stent (Berger 2007).  
 
Table (1.2): Thienopyridine Group Sales in Jordan (IMS 2010) 
This item has been removed due to third party copyright. The unabridged version of the thesis can be 
viewed at the Lanchester Library, Coventry University. 
36 
 
As shown in table 1-2 Plavix was ranked number one selling drug among its group in 
Jordan. 18,000 units of Plavix were sold in year 2009 out of 22,000 units sold from the 
same group. Plavix market share was 84.9% in the year 2009. After repeated 75-mg oral 
doses of clopidogrel (base), plasma concentrations of the parent compound, which has no 
platelet inhibiting effect, are very low and are generally below the quantification limit 
(0.000258 mg/L) beyond two hours after (Simon et al.2009). 
Clopidogrel is rapidly absorbed after oral administration of repeated doses of 75 mg 
clopidogrel (base), The pharmacokinetics of the main circulating metabolite are linear 
(plasma concentrations increased in proportion to dose) in the dose range of 50 to 150 mg 
of clopidogrel. Absorption is at least 50% based on urinary excretion of clopidogrel- 
related metabolites. Certain serious side effects include skin irritations, respiratory  
difficulties, bloody stools and vomit, bloating of facial features, limbs and joints, 
exhaustion etc. (Simon et al. 2009) 
- Co-Diovan is a drug that belongs to a class of medicines known as angiotensin II 
antagonists in combination (valsartan) with diuretics (hydrochlorothiazide). It is usually 









Table (1.3): Group of Angiotensin II Antagonists Sales in Jordan (IMS 2010) 
 
As shown in table 1-3, Co-Diovan was ranked number one selling drug in Jordan among  
its group in the year of 2009.  A total of 27000 units was sold out of 83000 unit sold for the 
whole group. Co-Diovan market share was 37.5% in the year 2009.Valsartan is rapidly 
absorbed after oral administration. 
 The mean absolute bioavailability of valsartan is 23% (range: 23±7%). The plasma 
concentrations in men and women were similar. If taken during a meal, the area under the 
plasma-concentration curve (AUC) for valsartan is reduced by 48% and the C max by 59%. 
However, from 8 hours after ingestion of valsartan in the fasting state or with a meal, the 
plasma concentration is comparable. The reduction of the therapeutic effect is so that 
valsartan can be taken independently of meals.  
This item has been removed due to third party copyright. The unabridged version of the thesis can be viewed 
at the Lanchester Library, Coventry University. 
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On the other hand hydrochlorothiazide is rapidly absorbed after oral administration (t max 
about 2 hours). The absolute bioavailability of hydrochlorothiazide after oral  
administration is 60-80%. 
More than 95% of the amount absorbed is excreted via the kidneys, in unchanged form. 
The most common side effects are: headache, dizziness, sensitivity to sun light and bright 
artificial light. (Briggs and Nageotte 2001). 
- Concor (Bisoprolol) is a drug belonging to the group called beta-blockers.  This group is 
used in cardiovascular diseases such as hypertension. It usually reduces blood pressure 
by blocking off the cardiac beta-receptors. It is also used to treat coronary heart disease, 
arrhythmias, and ischemic heart diseases (Medicine net. 2010).  
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Table (1.4): Group of Beta Blockers Sales in Jordan (IMS 2010) 
 
As shown in table 1-4 Concor was ranked number one selling drug among its group of 
(Beta Blocking Agents).  80,000 units of Concor were sold in 2009 out of 251,000 units 
sold of the whole group. Concor market share was 27.6% in the year 2009. 
Bisoprolol has both lipid and water-soluble properties making it a prime candidate over 
other β-blockers and even over other β1-blockers, being water soluble it will have 
decreased incidence of central nervous system side effects (inability to diffuse into brain) 
compared to purely lipophilic compounds. Bisoprolol has an approximate half-life of 10-12 
hours and when ingested has nearly complete absorption into the blood stream. The high 
This item has been removed due to third party copyright. The unabridged version of the thesis can be 
viewed at the Lanchester Library, Coventry University. 
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absorption is indicative of high bioavailability (approx. 90%). When being eliminated, the 
body evenly distributes it (50-50) between kidney excretion and liver biotransformation 
(then excreted). These factors make it a convenient once/day dosage when it is being 
administered.  
Beta-blockers can precipitate asthma and this effect can be dangerous. Beta-blockers should 
be avoided in patients with a history of asthma or bronchospasm. 
Following are the four medicines used in the analysis are: 
- Co-Diovan (160/12.5) tablets. 
- Concor (5mg) tablets. 
-  Lipitor (20 mg) tablets. 







































Review of Previous Counterfeit Pharmaceuticals Surveys 
In this section of the research, previous studies on counterfeit pharmaceuticals will be 
surveyed in order to provide solid theoretical background about this research problem. 
The trade in counterfeit drugs is responsible for increasing drug-resistance especially for 
infectious diseases, such as malaria (Bate et al. 2008).Counterfeit medicines also have a 
negative impact on public perceptions of the effectiveness of pharmaceuticals. 
Several studies were examined and indicated that the developing countries and the poorer 
countries are most affected by the counterfeit problem  
In discussing counterfeit medicine, researchers usually used the term substandard medicine 
to refer to genuine medicines that are produced by legitimate manufacturers and which do 
not meet the quality specifications that the producer says they meet. Normally they contain 
active ingredient at doses less than the label claims (Caudron et al. 2008).  
 The most common source for substandard medicines is batches of a drug that fail one or 
more tests due to some manufacturing problem. Normally, they should have been destroyed 
but instead they get in some way into the legitimate distribution channel and consequently 
get into the market. 
 Another source is improper storage at high humidity or high temperature, which might 
affect the active ingredient in the drug, and could cause microbial contamination (Morris 
and Stevens, 2006). 
Studies have indicated that 14 million people die every year of infectious diseases, 90% of 
them from the developing countries (Newton et al. 2006 b). 
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To test for counterfeit presence previous studies have utilised a number of testing methods 
such as a simple die test, thin layer chromatography (TLC), high performance liquid 
chromatography with UV detection (HPLC -UV), high performance liquid chromatography 
with diode array detection (HPLC-DAD), near infrared spectroscopy (NIR), disintegration 
tests, and dissolution tests. 
Following are the previous studies, which have been used in this research. 
 
2.1 Anti-malarials Pharmaceuticals 
Malaria is usually caused by a parasite called plasmodium falciparum. Malaria remains 
globally the most important parasitic disease, with approximately one million deaths caused 
by Malaria each year (Tipke et al. 2008).  Anti-malarial pharmaceuticals are among the 
most widely consumed drugs in tropical countries that have been particularly targeted by 
counterfeiters (Onwujekwe 2009).   
This has created a high demand for anti-malarial medications consequently; this may 
explain why counterfeiters targeted anti-malaria pharmaceuticals. 
 
2.1.1 Anti-malarials Pharmaceuticals in Africa 
The level of the presence of counterfeits and sub-standard pharmaceuticals in African 
markets is considered a serious problem that causes many deaths each year. It is known that 
malaria is a major cause of morbidity and deaths worldwide. The most deadly form of the 
malaria parasite is known as Plasmodium falciparum, which is prevalent primarily in sub-
Saharan Africa (SSA) (Amin and Kokwaro 2007).  
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In tropical countries in Africa, pregnant women and young children under 5 years of age 
account for 90% of victims (WHO 2003 b). 
Because of the fact that Africa suffers from a high incidence of malaria and so there is a 
great demand for these medications across the continent, this has created more incentives 
for the counterfeiting trade.  
 The following studies were conducted on anti-malarial medications to evaluate the quality 
of the medication used.      
1- In a study conducted in South East Nigeria to evaluate the quality of anti-malarials in the 
country (Onwujekwe et al. 2009) researchers have collected 225 samples of anti-
malarials which include artesunate, dihydroartemisinin , sulphadoxine- pyrimethamine 
(SP), quinine and chloroquine, this study was conducted  in six towns (three urban and 
three rural) in Anambra state, south-east Nigeria. The samples were collected from 
randomly selected providers. The sample size was determined based on the range of 
providers and feasibility and was selected from a broader study of the nature of malaria 
treatment provision. In the broader study, 50 providers (public and private) in each urban 
and 25 in each rural area were selected, thus total sample size was 225 providers. The 
quality of drugs was evaluated through the purchase of anti-malarial drugs from a 
random sample of 20% of the 225 selected providers. They were spread out across the 
different levels of providers, but all existing public providers in each study area were 
included in the study. 
The providers were divided into low-level providers and high/medium level providers. The 
low-level providers included patent medicine dealers, mixed goods shops and maternity. 
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The quality of these samples were evaluated by performing dissolution profiles using the 
United States Pharmacopoeial specifications for the monograms and high performance 
liquid chromatography (HPLC) to detect the quantity of the active ingredients in the 
samples.  
 Findings for HPLC analysis showed that 60 or 37% of the anti-malarials did not meet the 
(USP) specifications regarding the amount of active ingredients.  Some of the drugs did not 
contain any active ingredient at all while others have active ingredient but with less 
quantity than was required.  Results of dissolution tests revealed that 46% of the quinine 
and 39% of sulphadoxine -pyrimethamine (SP) formulations did not meet the tolerance 
limits that were required in the USP monograms.  
Findings indicated that 78% of the samples that did not meet the (USP) tolerance limits 
were found in private facilities especially low-level health care providers. These private 
health care providers usually work in health care facilities that have many years of formal 
training but with no formal education and 94.5% of those providers are licensed.   The 
researchers have concluded that there was a high existence of poor quality drugs in the 
country. 
Findings have clearly indicated that there was a high prevalence of many substandard anti-
malarial drugs in the study area.  
The strength of this study was the large sample size and suitable methodology, which 
included the use of the powerful testing method of USP. The random sampling technique 
and the multi-level classification of the samples can also be considered as major strengths 
of the study. 
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2- Bate et al. (2008 )collected  210 samples of mefloquine, artemether, amodiaquine, 
artesunate, dihydroartemisinin, and artemether-lumefantrine fixed-dose combinations   
from private pharmacies in urban and semi-urban areas in the major cities in six  African 
countries. 
The quality of these samples was chemically tested by performing thin-layer 
chromatography (TLC) and dissolution testing. 
 The Global Pharma Health Fund Minilab was used to run semi-quantitative thin-layer 
chromatography (TLC) and dissolution tests on each sample to determine the presence and 
relative concentration of active ingredients. Each test was done twice. The Minilab 
protocols award products a “pass” if they have 80% or more of the labeled active 
ingredients. For fixed-dose combinations and SP, “pass” was awarded only if both active 
ingredients met this standard. 
Findings indicated that 35% of the samples analysed failed either TLC or dissolution or 
both tests.  Researchers have identified the existence of artemisinin mono therapy, which is 
rejected by the world health organisation (WHO) and considered as substandard treatment 
even when its dosage is correct. The researchers found that 33% of the samples were 
artemisinin mono therapy, and 42% of them failed either TLC or dissolution tests. 
Again, findings confirmed the presence of substandard and clinically inappropriate 
medicines in the country. 
This study followed a precise research protocol, which has generated reliable results. The 
sampling procedures were conducted in a way that guarantees good representation of 
different geographic areas.  
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3- In Sudan, (Alfadl et al. 2006) collected 50 samples of the most used anti-malarial drugs 
such as; chloroquine, quinine, artemether and mefloquine in different dosage forms; 
tablets, syrup, suspension and injections.  
Six states in northern, eastern, western and central Sudan were chosen for sample collection 
to represent all Sudanese markets. 
The sampling procedures were designed in a way to determine whether these procedures 
were adversely affected by transport and storage conditions. 
The quality of these samples was physically and chemically assessed. Chemical analysis 
was performed to determine the content of the active ingredients.  Results indicated that 
84% suffered physical failures especially for injections due to a change of colour were 
observed, 8% failed due to low content of the active ingredients in chloroquine tablets and 
8% failed due to low dissolution rate for the same drug. 
The researchers concluded that the physical failure might be due to transport and storage 
conditions.  They concluded that the problem of substandard anti-malarial drug products is 
actually circulating in the Sudanese market. 
Non-suitable distribution mechanisms as well as non-suitable storage conditions and non-
compliance with good manufacturing practice (GMP) guidelines by manufacturers in 
production also seemed to have contributed to these results. 
One major strength of this study was the countrywide coverage (all parts of Sudan were 
included in the sampling selection) which had made comparative evaluation possible using 
standard testing methods thus yielding reliable results.  
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2.1.2 Anti-malarials Pharmaceuticals in Southeast Asia 
The problem of counterfeit and substandard drugs is a major concern in Southeast Asia. 
Malaria has become resistant to most of the available anti-malarial medications. Resistance 
develops from the exposure of the human malaria parasite to a non- therapeutic 
concentration of an anti-malarial drug. 
The following studies were conducted in Southeast Asia to evaluate the quality of anti-
malaria medications in the country: 
1- In Cambodia, a study of 451 drug samples was conducted (Lon et al. 2006). Samples 
included mefloquine hydrochloride, tetracycline tablets/ capsules, dihyro artemisinin 
(DHA) tablets and artemether tablets. 
The national and regional project teams were trained in the sampling method, 
good laboratory practices and basic drug testing techniques, including physical and visual 
inspections, simple disintegration, thin layer chromatography (TLC), data documentation 
and reporting. Three rounds were conducted in different areas of the provinces. The first 
round was conducted in April 2003. The drug outlets in a capital town of each province 
were selected using a pre-defined sampling protocol. The second and third rounds covered 
other drug outlets in the different districts in July and December 2003. 
A sample from each lot of anti-malarial drugs was purchased.  Samples were then subjected 
to testing procedures. The first level was basic testing performed at the sites using testing 
methods and procedures described in the Global Pharma Health Fund Minilab kit. The third 




The quality of these samples was chemically assessed by simple disintegration and thin 
layer chromatography (TLC). 
Results indicated that, 71.8% of the 85 quinine samples failed, 19.8% of the 81 artesunate 
samples failed, 7.7% of the 39 mefloquine samples failed, 8.5% of the 94 chloroquine 
samples failed and 26.6% of the 128 tetracycline failed.  
Some of the failed samples were due to lack of active ingredients from the required amount. 
Some of them have no information related to the manufacturer or the origin of the product 
while some have fake holograms. 
The researchers concluded that there is evidence of counterfeit and substandard anti-
malaria drugs in Cambodia. Results of this study seemed to confirm that counterfeit and 
substandard pharmaceuticals are circulating in the country.  
The major strength of this study was the training sessions held for the research team 
personnel prior to the beginning of the research process. This method contributed to 
reaching significant reliable results. 
2- A study was conducted after the death of a 23-year old man from Burma who died after 
taking the drug artesunate, which is normally very effective for malaria treatment 
(Newton et al. 2006 b).  This case was investigated by a team of experts from Oxford 
University. The analysis was conducted by applying mass spectrometry to identify the 
active ingredients in the medicine and high performance liquid chromatography to 
determine the amount of the active ingredients in the medicine.  Results indicated that, 
the main active ingredient was paracetamol (acetaminophen), which can temporarily 
lower malarial fever but does not kill the parasite.  Only 20% of the active ingredient 
was present, 10 mg per tablet instead of 50 mg, which was stated on the label. In the 
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same study the researchers reported that the percentage of over-the-counter counterfeit 
pills that contain no artesunate have increased from 38% to 52% in Southeast Asia from 
1999 through 2004. 
Results of the study on this case have confirmed the danger of the existence of substandard 
or fake anti-malarial medications. 
 
2.1.3 Anti-malarials Pharmaceuticals in Yemen 
In Yemen, Malaria has always been viewed as a major public health problem. It is believed 
that treatment failure associated with drug resistance may also be due to poor 
pharmaceutical quality. 
Abdo-Rabbo, Bassili and Atta (2005) have conducted a study with the objective of 
assessing the quality of anti-malarial drugs that are commonly used in the country, 
particularly Chloroquine Phosphate tablets (CQT), Chloroquine Phosphate syrup (CQS) 
and Sulfadoxine/ Pyrimethamine tablets (SPT). Researchers included four samples from 
each anti-malarial product from various levels of the distribution chain. 
Four samples from each anti-malarial product were collected from each of the various 
levels of the distribution chain. One sample was kept with the research team. Two were 
tested at Sana'a and Aden Drug Quality Control Laboratories. The fourth was sent to the 
Centre for Quality Assurance of Medicines in Potchefstroom, South Africa, for analysis. 
Quality indicators measured were the content of the active ingredient and dissolution rate 




The analysis of the samples was conducted using a high pressure liquid chromatography 
(HPLC) method, and dissolution testing was performed for tablets only. Results indicated 
that the content of the active ingredients for (CQT) fails the standard limit significantly by 
20%, and some dissolution failure for the same drug. As for (SPT) active ingredient was 
found within the standard limits content but showed a high failure rate in the dissolution 
testing.  
Results seemed to indicate that the failure detected in this study could be considered as a 
serious problem. This problem indicates that there is sub-standard anti-malarial products 
circulating within the drug distribution chains in Yemen, and the dissolution failure 
indicates a non-compliance with good manufacturing practice guidelines by the 
manufacturer in the production of anti-malarial pharmaceuticals. 
Researchers recommended that, an intervention plan should be developed and implemented 
immediately in Yemen. This may involve establishing quality surveillance systems within 
drug regulatory authorities in the country. The objective of these systems to provide the 
required support to manufacturers to improve Good Manufacturing Practice (GMP) 
compliance and promote effective management of drug supply. 
The lessons that should be drawn from this study could be significant in helping Yemen to 








2.2 Antibiotics Pharmaceuticals 
There is growing global concern regarding counterfeit antibiotics medications. In particular, 
counterfeit antibiotic drugs are increasingly viewed as a major threat to public health with 
many serious consequences for patients in terms of increased mortality and morbidity and 
drug resistance. 
Recent research has indicted that, all types of pharmaceutical products have been involved, 
particularly antibiotics and anti parasitic agents, are the most counterfeited products in 
developing countries. 
 
2.2.1 Antibiotics Pharmaceuticals in Pakistan 
Pakistan ranked 13th in world for the practice of producing and selling counterfeit 
pharmaceuticals. Obaid (2009) conducted a study to evaluate the quality of ceftriaxone 
sodium which is widely used as a third generation cephalosporin (antibiotic) in the country 
the researcher collected 96 random samples of different strength injections (250, 500 and 
1000 mg)  from different pharmacies,  medical stores,  and hospitals in the country.  The 
quality of these samples was evaluated by utilising the United States’ pharmacopoeia (USP 
2006) method with 90-115% limits to perform high performance liquid chromatography 
(HPLC) to evaluate the content of the active ingredients. 
Findings indicate that 15.62% of the samples were out of pharmacopoeial specifications 
(90-115%). It showed that none of the samples was counterfeit but 7.29% of them were 
found to be above the limits ranging from 116 to133%, and 7.29% of them were below the 
lower limit ranging from 55 to 89% of the active ingredients.  
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The researcher concluded that there are ceftriaxone sodium injections in the country outside 
the pharmacopoeial specifications and there are manufacturers that do not comply with 
good manufacturing practices. 
 
2.3 Anti- Parasitic Pharmaceuticals 
Again the problem of counterfeit pharmaceuticals seem to influence all parts of the world 
even those very well protected health systems such as the Japanese health system. 
 
2.3.1 Anti-Parasitic Pharmaceuticals in Japan 
In Japan a pilot study was conducted (Aka et al. 2005), to assess the quality of theanti-
parasitics, Albendazole and Mebendazole, in the country. Researchers selected these 
medications due to high demand for the use on worm infections which was widely used in 
Japan since there is worm infection prevalence in the country.  To carry out their study, 
researchers have collected 44 samples of these medicines (15 Albendazole and 29 
Mebendazole).  
These samples were collected from 22 street vendors, in four cities in Japan. The testing of 
these samples included physical appearance and chemical testing which was performed by 
using thin layer chromatography (TLC) and high performance liquid chromatography 
(HPLC). The findings have confirmed the existence of the counterfeit medicine, where 9 
out of 44 (20%) of the samples were found to be counterfeited.  Results also showed that 
one sample of Albendazole was not produced by the labeled manufacturer and another 
sample was deliberately similar to a genuine one showing the same features but not the 
same amount of the active ingredient.  
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One sample of Mebendazole did not have any spot on the TLC plate, which means there is 
no active ingredient in the drug and that was confirmed after HPLC analysis was performed 
on the same sample. Three samples had incorrect registration numbers and their 
manufacturers were unknown; two samples had fake names and addresses, and one sample 
had an unregistered market name.   
The results of this study seem to confirm the fact that counterfeiters can penetrate any 
health system regardless of how strong and protected it is. 
The sampling procedures utilised in this study seemed to be suitable but the sample size 
was somewhat small in comparison with the size of the Japanese market. 
 
2.4 Stimulant Pharmaceuticals 
Amphetamine, the first manufactured stimulant, as well as fenethylline hydrochloride. 
Fenethylline hydrochloride (captagon) has been an extensively abused drug in many parts 
of the world. Due to their high degree of abuse and tendency to induce psychological 
dependence, their use is usually restricted to a few clinical conditions. 
 
2.4.1 Stimulants in Saudi Arabia 
In Saudi Arabia (Al-Hussaini 1996), a study was conducted to analyse the characteristics of 
captagon tablets, which has Fenethylline as the active ingredient. A total number of 900 
batches of captagon tablets seized by drug controlling authorities were used as samples for 
the study.  Each sample contains between 10 and 50 tablets, 10 tablets from each batch 
were used for the analysis. The samples were tested for their physical appearance such as 
(colour, hardness, diameter and markings) and their chemical characteristics. Physical 
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appearance indicated that all the seized tablets were narrower in diameter and thicker than 
the genuine captagon tablets. Also, the seized tablets were found to have two different 
colours (white and cream).  The white group colour when analysed chemically were found 
to contained fenethylline with caffeine and /or quinine.  While the other group, instead of 
having fenethylline, had a different compound. The chemical analysis was performed by 
thin-layer chromatography (TLC), it was noticed that some of the suspected captagon 
seized during 1990-1993 were found to contain pure paracetamol mixed with ephedrine in 
10% of the samples while 13% of the samples contained amphetamine and ephedrine and 
some of the samples did not contain any compound but they appeared to be similar to the 
genuine tablets. The researcher concluded that the majority of the samples lack the active 
ingredient (fenethylline) which is the major active ingredient and instead other ingredients 
are replaced.  
Researchers have also noticed that the trade of this drug continues, probably from the same 
source, and the composition of the tablets depends on the availability of the active 
ingredients during the time of manufacture. 
This study seemed to be very significant in Saudi Arabia because it shed light on the 
counterfeit problem, which should facilitate policy-making measures to fight against this 








2.5 Previous Studies in Jordan 
Two previous studies indicated that there was a problem with counterfeit anti-biotic and 
stimulants in Jordan. 
 
2.5.1 Previous Study on Antibiotics  
In an attempt to evaluate the quality of antibiotics in developing countries, (Kyriacos et 
al.2008) collected samples of amoxicillin in different formulations produced locally and 
comparable sample from imported drugs.  
The countries included in the study sample were Lebanon, Jordan, Egypt and Saudi Arabia. 
One hundred and eleven samples of amoxicillin capsules and suspensions from different 
pharmacies were collected and analysed using chromatographic methods to determine their 
content of the active ingredients. 
Findings indicated that 56% of amoxicillin capsules did not meet the United States 
pharmacopoeia (USP) requirements, 8% of the samples of suspensions did not meet the 
pharmacopoeial limits, while the entire European brands met the pharmacopoeial limits 
except in one sample.  
Researchers concluded that there were substandard medicines in the market of the tested 
countries. The existence of substandard medicine especially for antibiotics might cause 
treatment failure and produce drug resistance.  
This particular study has confirmed the existence of substandard antibiotics in many 
middle-eastern countries among them was Jordan. 
One major weakness however, was the small sample size, which was only 111 units of the 




2.5.2Previous Studies on Stimulants 
Another study was conducted on a stimulant drug called Captagon, which has Fenethylline 
as the active ingredient (Albdalla 2005). This drug is known to be abused especially by 
young people and has been controlled since 1988 by The Drug Control Department of 
Public Security Directorate. One hundred twenty-four batches were seized by drug 
authorities and analysed to identify the composition of the drug.   The findings of the study 
indicated that the majority of the samples lack the active ingredient (Fenethylline) which 
had been replaced by other ingredients such as caffeine, amphetamine and several other 
ingredients found in the drug.   These ingredients were capable of inducing the same action 
as the genuine active ingredient. 
These studies have contributed to the Jordanian government’s extensive measures to deal 
with counterfeiting of pharmaceuticals. These measures included increasing penalties and 
other actions related to the importation and analysis of pharmaceuticals. 
Therefore, the investigation of the impact of these measures made this research important to 


























3. Sampling Methodology 
This study includes testing four types of life saving medications manufactured by leading 
pharmaceutical manufacturers used in Jordan, which have been usually targeted in the past 
by counterfeiters due to their relative high prices. 
In 2008, there were 1720 Pharmacies; pharmacies were selected as a sample for this study. 
The sampling was conducted in three stages. 
The researcher collected samples of these medications from 33 community pharmacies in 
different districts of Amman for the first stage. Table (3.1) shows the number of districts 
and the number of selected pharmacies in each district. 
The medicine found to be most counterfeited was planned to be included as a sample in the 
subsequent stage.  
Collected samples were labeled , coded and  information posted for each drug such as name 
of the sample, strength of the dosage form, location of the sample, the date of manufacture, 
the date of expiry, the batch number, the date of purchase and the name of the source. 
To determine the genuine medicine from the counterfeited one, the physical appearance and 
the chemical were used as quality indicators in the analysis.  
Tests included the use of Pharmacopoeial methods of high performance liquid 
chromatography (HPLC) for each medicine in the sample except for Lipitor, which was 
tested using dissolution test in addition to HPLC.  
In order to have a clear idea about the medicines this study is going to test, a pilot study 
was conducted. Ten pharmacies were selected from the five areas of Amman and four 
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medications from each pharmacy were bought and subjected to lab analysis. These samples 
were coded and information about each medicine were posted, such as:  name of the 
sample, strength of the dosage form, location of the sample, the date of manufacture, the 
date of expiry, the batch number, the date of purchase and the name of the pharmacy were 
documented. 
 
3.1 Sample Collection 
The sampled medicines are Lipitor (atorvastatin-calcium) a cholesterol lowering drug, 
Concor (bisoprolol fumarate) for hypertension, Co-Diovan (valsartan, hydrochlorothiazide) 
which is used to regulate blood pressure and Plavix (clopidogrel) a drug taken to prevent 
blood clots. 
Sample collection included two types of medicines as follows: 
1- Collecting samples of confiscated counterfeit medicines from official channels. Jordan 
Food and Drug Administration (JFDA) was the source of theses samples which usually 
obtains all confiscated products from customs authorities. This process was conducted 
in order to validate the testing procedures and ensure that the chemical analysis as well 
as the physical testing can distinguish between genuine and counterfeited 
pharmaceuticals. 
2- Collecting samples of the four medicines circulating in the market. This process was 




3.1.1 Stage One 
Stage one includes the process of  selecting thirty three pharmacies from the Amman area 
the capital of Jordan which represent 3.1% of total pharmacies in Amman (1063) and   
1.9% of total number of pharmacies (1720) in Jordan. Four selected drugs from these 
pharmacies were bought and included in the lab analysis. Results of this process should 
determine the most common counterfeited drug from the four chosen drugs.  The 
counterfeited drugs, if available was planned to be used for the next stage. This process 
provided the researcher with an opportunity to evaluate the magnitude of the counterfeit 
problem in the four different drugs and to identify if the problem is located in certain 
specific pharmacies.   
For the sampling purposes, Amman the capital of Jordan which contains 1063pharmacies, 
was divided into five areas ( north, east, south, west and the center of the city) in order to 
make the sampling procedures more accurate, and more representative as shown in Table 
(3.1). 
Table (3.1) shows the different districts of Amman and number of pharmacies in each of 
them used in the analysis. 
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East Amman 156 5 14.1% 
West Amman 297 9 27.8% 
North Amman 162 5 15.2% 
South Amman 157 5 14.8% 
City Center 293 9 27.6% 
Total 1065 33 99.5% 
 
The total number of sampled pharmacies were selected from each district and used in the 
analysis. 
The first seventeen pharmacies were selected randomly from different areas in Amman, 
while the other sixteen pharmacies were selected from poor areas and pharmacies known to 











3.1.2 Stage Two 
Based on the study results after finishing the analysis, the most commonly counterfeited 
drug would be purchased from an additional 40 pharmacies for the investigation of stage 
two. 
Figure (3.1):  Map showing the three major populated cities (marked with red) 
 
These samples should be chosen from the three largest cities in Jordan as shown in figure 
(3.1), The total number of pharmacies in Amman,  Zarka, Irbid  were 1063, 278 , 205 
respectively. This will make the total sample to be 73 pharmacies out of the 1546 in the 
three cities (i.e. 4.7%) and 4.3% from1720 in whole of Jordan. 
Consequently, a clear idea of the national distribution of the counterfeit problem should be 
gained. 
This item has been removed due to third party copyright. The 3 cities highlighted 
are Amman, Zarka & Irbid.  The unabridged version of the thesis can be viewed at 





















4. Analytical Methodology 
This chapter presents the lab testing. The researcher would like to say that this study was 
not directed to any specific drug, but instead it aimed at the determination of whether 
counterfeit products do exist in the country or not. 
This research has been conducted through two phases: 
Phase One: this phase describes the physical as well as chemical analyses of samples of the 
four pharmaceuticals obtained from Amman area.  
 
4.1 Laboratory Chemical Testing 
Quantitative testing was performed using high performance liquid chromatography. This 
method has the ability to accurately quantify the active ingredients present in the 
pharmaceutical preparations.  
High performance liquid chromatography is a testing method used frequently to separate, 
identify and quantify the compounds. It consists of a stationary phase (column) and a 
mobile phase, which moves through the column, and a pump provides high pressure to 
move the mobile phase.  
The major advantage of HPLC is that it is a sensitive, accurate and precise method of 
analysis. It allows a complex analysis to be done in a defined period of time and can 
accomplish the baseline resolution of components  (Ho and Lin 1996). 
HPLC is considered widely as a stability indicating method which selectively separates 
each active ingredient from its degradation products and in addition separates it from its 
process impurities and formulation excipients (Ho and Lin 1996). 
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Therefore, this testing method has a qualitative as well as quantitative nature. It also has the 
ability to detect the related impurities in the product. The process was performed according 
to pharmacopoeial specifications. 
 
4.2 Drug References and Reagents 
 The Jordanian Pharmaceutical Manufacturing   Co. (JPM) sponsored all chemicals used in 
the lab testing. 
The following drug references were used:  
 Bisoprolol Fumarate   obtained from Moehs /Barchelona, assay 100.55%, water content 
0.12%. 
 Atorvastatin Calcium obtained from Biocon/ India, assay 98.5%, water content 4.0%. 
 Clopidogrel Bisulphate obtained from Indu-swift/India, assay 98.0%, water content 3%. 
 Related Impurities for Plavix and Co-Divan were USP references. 
 Valsartan obtained from Ranbaxy Lab /India, assay 98.15%, water content 0.94%. 
 Hydrochlorothiazide obtained from Shilton/India, assay 100.3%, water content 0.08%. 
The following excipients and reagents were used: 
 Tannic Acid obtained from Merck/ Germany. 
 Methyl Alcohol for HPLC obtained from Acros organics /New Jersey, USA. 
 Acetonitrile obtained from Merck /Germany. 
 Potassium Dihydrogen phosphate (KH2PO4), obtained from Merck /Germany 
 Phosphoric Acid 85% reagent grade obtained from (GFS) chemicals/ Germany. 
 Acetic Acid obtained from Merck/ Germany. 
67 
 
 Ammonia obtained from Merck/ Germany. 
 Sodium Hydroxide pellets obtained from Acros Organics/ New Jersey (USA). 
 
4.3 Profiles of medications used in the analysis 
Table (4.1) summarises some basic characteristics of the selected medicines in terms of 
active ingredients, dosage forms, strength, and number of samples. 
 




































Method of Analysis 
All chemical tests for the study samples in this thesis have been done using high 
performance liquid chromatography for assay and related impurities. This method was 
adopted from the United States Pharmacopoeia (USP). 
The United States pharmacopoeia (USP) is a collection of quality specifications for 
pharmaceutical substances and dosage forms together with general methods of analysis. 
A monograph includes the name of the ingredient, the definition, packaging, storage, 
labeling requirements, and the specifications that the product must maintain in order to be 
ready for administration to patients. 
 The detailed specifications determined by pharmacopoeia are to be implemented to ensure 
the quality of pharmaceuticals which affect the safety and effectiveness of the drug.  These 
specifications are usually enforced by authority in the country of manufacture using 
pharmacopoeial standards to ensure compliance (US Pharmacopoeia 2010). 
 
4.3.1 Co-Diovan Analysis 
Following are detailed description of Co-Diovan (160/12.5) analysis. 









1- (C24 H29 N5 O3). The chemical structure is shown in Figure (4.1) (Marks 2007). 
Figure (4.1): Chemical Structure of Valsartan 
2- (C7H8ClN3O4S2). The chemical structure is shown in Figure (4.2) Beermann, 
Groschinsky-Grind and Rosen (1976). 
Figure (4.2): Chemical Structure of Hydrochlorothiazide 
Indications: Treatment of blood pressure (hypertension). 
Dosage: One tablet daily. 
The price: JD 31.75(£27.10) per pack which contains 28 film-coated tablets. 
Manufacturer:  Novartis pharma   (Switzerland) 
This item has been removed due to third party copyright. The 
unabridged version of the thesis can be viewed at the 
Lanchester Library, Coventry University. 
This item has been removed due to third 
party copyright. The unabridged version of 
the thesis can be viewed at the Lanchester 
Library, Coventry University. 
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In this research Co-Diovan was subjected to physical as well as chemical analyses. Physical 
testing conducted by visual inspection of the package. 
 
 Method of Analysis 
Co-Diovan was chemically tested using high performance liquid chromatography for assay 
and related impurities. This method was adopted from the United States Pharmacopoeia 
(USP) verified in terms of linearity. Verification process indicated that this method is linear 
in the determination of valsartan and hydrochlorothiazide in Co-Diovan tablets. The 
linearity range for valsartan was between 10.002-30.006 mg/100ml, and linearity range for 
Hydrochlorothiazide was 0.798-2.394 mg/100ml. 
The mobile phase consists of two solutions: 
1. Solution A- a filtered and degassed mixture of water, acetonitrile, and trifluoroacetic 
acid (90: 10: 0.1) was prepared. 
2. Solution B- a filtered and degassed mixture of acetonitrile, water, and trifluoroacetic 
acid (90: 10: 0.1) was prepared.  
 
Standard and Sample Preparation for Analysis 
Diluents:  a mixture of acetonitrile and water (1:1) was prepared. 
For standard preparation: 160 mg of valsartan working standard and 12.5mg  of 
hydrochlorothiazide working standard were weighed and transferred into 200ml volumetric 
flask then the volume  made up to 200 ml with solvent,5ml of this solution was diluted to 
20 ml with  the same solvent. 
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Sample preparation for assay and related impurities: 20 tablets were weighed and powdered 
then an equivalent to 160 mg of valsartan was weighed and transferred into 200ml 
volumetric flask and 100ml of diluents(a mixture of acetonitrile and water (1:1)) was added 
then sonicated for 30 minutes. After that, the volume was made up to 200 ml with the 
diluents,  a portion of this solution is centrifuged at 3000rpm for 15 minutes, 5ml of the 
clear supernatant is diluted to 20 ml by diluents, and used for the analysis for assay and 
related impurities. 
For the preparation of related impurities: (3.6 mg of USP Benzothiadiazine related 
compoundA, valsartan related compound A (S)-N-butyryl-N-((2-(1H-tetrazole-5-yl)-
biphenyl-4-yl)-methyl1)-valine(Ivanovic, Malenovic and Jancic 2007), 6.1 mg of 
hydrochlorothiazide, 8.5mg of valsartan, and 20.5mg (valsartan related compound B ) are 
placed into 100ml volumetric flask the volume  made up to 100 ml with solvent which 
contain acetonitrile: water with the ratio (1:1), then 5ml of this solution is diluted with 
diluents to 100 ml, 5ml of this solution is taken and  the volume  made up to 50ml with 
solvent. This is then used for the HPLC analysis. 
The samples were analysed by HPLC to confirm the amount of the active ingredients. 
The high performance liquid chromatography (HPLC) apparatus consists of Thermo spectra 
system which is equipped with a pump (P 2000), an auto sampler spectra system (AS 
3000), UV detector with UV lamp and data processor (chromquest software) the 
chromatographic column was Hichrom Kromasil KR, C18, (100mm x 4.6nm) containing 
5µm packing L1. 
The detection wavelength used was 265nm, the flow rate was 0.4ml/min, and the injection 
volume was 10µl.  
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The chromatograph is programmed as follows: A gradient elution of solution A, and B was 
used during the chromatographic system as indicated by the (USP) method as shown in 
Table (4.2). 
Table (4.2): The HPLC Gradient Programmed for the Analysis of Co-Diovan 
Time   (minutes) Solution A (%) Solution B (%) Elution 
0-25 90-10 10-90 Linear gradient 
25-27 10-90 90-10 Linear gradient 
27-40 90 10 Isocratic 
 
Calculations: Following are methods utilised in the calculation of assay and related 
impurities: 
 
Calculation for assay: Final Concentration (F.C) for the standard was calculated by the 
equation: 
F.C. (standard) = (Standard weight/dilution)*(dilution factor) *(assay of the standard %)* 
(100-water content %)*100% 
Final Concentration for the Sample was calculated by the equation: 
F.C. (sample) = (sample weight/dilution)* (dilution factor) *(tablet strength /tablet weight) 
* 100%.                                                   
Calculation for the assay of the sample was calculated by the equation: 
Assay for the sample % = (Average area for the sample /F.C. for the sample) *(F.C. 
standard) /average area for standard) *100% 
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Calculation for the related impurities: 
Impurity B and other impurities were calculated by the equation: 
Assay = (Final concentration for impurity B/ peak area for impurity B in diluted standard) 
X (Peak Area for impurity B and other impurities) / (Final concentration of Valsartan in the 
prepared sample)] X 100%. 
 
4.3.2 Plavix Analysis 
Following are detailed description of plavix analysis: 
Active Ingredient: 75 mg of clopidogrel bisulphate (C16H16 ClNO2S). Chemical structure   
Is shown in Figure (4.3) (Pereillo et al. 2002). 
 
 
Figure (4.3): Chemical Structure of Clopidogrel Bisulphate. 
Indications:  Plavix is taken to prevent blood clots (thrombi) forming in hardened blood 
vessels (arteries).a process known as atherothrombosis, which can lead to atherothrombotic 
events (such as stroke, heart attack, or death). 
Dosage:  One tablet a day. 
Price: JD 73.83 (£63.10) per pack which contains 28 film-coated tablets. 
Manufacturer: Sanofi-synthelabo (France). 
This item has been removed due to third party 
copyright. The unabridged version of the thesis 




Thirty three samples of Plavix was collected and subjected to physical as well as chemical 
Analysis. 
Physical testing included visual inspection of the package 
 
Method of Analysis  
The chemical analysis for Plavix (clopidogrel bisulphate) tablets was performed by using 
High performance liquid chromatography for assay and related impurities.      
The method used was from the United States Pharmacopoeia (USP), which was verified in 
terms of linearity, the results indicate that this method is linear in the determination of 
clopidogrel in Plavix tablets, the range between 5-15 mg/100 ml, accurate, and precise. 
 
Standard and Sample Preparation for Analysis 
Phosphate buffer was prepared by weighing and dissolving 1.36 gram of potassium 
dihydrogen phosphate in 1000ml of water. 
For mobile phase: a filtered and degassed mixture of phosphate buffer and acetonitrile 
(80:20) was prepared.   
For standard preparation: 50mg of clopidogrel bisulphate was weighed and diluted in 
100ml methanol, 5ml of this solution then diluted with 25ml methanol. 
For sample assay and related impurities preparation: 20 tablets were powdered and weighed 
carefully, a portion of the powder which was equivalent to about 75mg of clopidogrel was 
weighed and transferred to a 100ml volumetric flask, 50ml of methanol was added and 
sonicated for 30 minutes then completed to volume with methanol. 
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A portion of this solution was filtered through 0.45µm porosity and used for the related 
impurities analysis. 
      For the analysis of the assay: 5ml of this solution was diluted to 50 by methanol, and then 
the solution was used for the HPLC analysis. 
For related impurities: 10.35mg USP Clopidogrel Related Compound A,15.15mg USP 
Clopidogrel Related Compound C and 2ml stock Clopidogrel Bisulphate stock standard 
were added to 50ml volumetric flask, volume was completed to 50 ml with methanol, then 
5 ml of this solution volume made up to 200 ml with mobile phase. And used for the 
analysis of related impurities of HPLC. 
The high performance liquid chromatographic system (HPLC) apparatus (TSP4) which 
consists of Thermo spectra system which is equipped with a pump (P2000), an auto 
sampler spectra system As (3000), UV detector with UV lamp, and data processor, the 
chromatographic column was Ultron ES-OVM, 150*4.6mm, 5µm and Pre-column:  ES-
OVM, 10*4mm.       
The detection wavelength used was 220-nm; the flow rate was 1.0 ml per minute. The 
injection volume was 10µL. 
 
Calculations: Following are methods utilised in the calculation of assay and related 
impurities: 
Calculation for assay: Final Concentration (F.C) for the standard was calculated by the 
equation: 
F.C. (standard) = (Standard weight/dilution)*(dilution factor)*(assay of the standard %)*   
(100-water content %) * (419.9/321.82) * 100%. 
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Where 321.82 is the molecular weight of clopidogrel; 419.90 is the molecular weight for 
bisulphate. 
Final Concentration for the Sample was calculated by the equation: 
F.C (sample) = (sample weight /dilution)* (dilution factor)* (tablet strength /tablet weight) 
* 100% 
Calculation for the assay of the sample was calculated by the equation: 
Assay for the sample % = (Average area for the sample /F.C. for the sample) *(F.C. 
standard) /average area for standard) *100% 
Calculation for the related impurities: 
Final Concentration for diluted standard was calculated by the equation: 
F.C (diluted Standard) = (standard weight/ dilution) *(dilution factor) * (assay for the 
standard %) * (100-content of water %)*(419.9/321.82)*100% 
Final Concentration for sample for related impurities was calculated by the  
 Equation: 
 F.C. (sample)= (sample weight/dilution) * (tablet strength/ Tablet weight) 
*(419.9/321.82)* 100% 
Calculation for assay for impurity A was calculated by the equation: 
Assay for impurity A = (average area for impurity A / F.C. for the related sample) * (F.C 
for Imp. A  in the diluted standard / average area for Imp. A for the diluted standard)*100% 
Calculation for impurity C was calculated by the equation: 
Assay for Impurity C= (Impurity C average area/ F.C. for the related sample) * (F.C for 




4.3.3 Concor Analysis 
Active Ingredients: 5mg of   Bisoprolol Fumarate [(C18H31 NO4)2.C4H4O4]. 
Chemical structure is shown in Figure (4.4) (USP Monograph 2007). 
Figure (4.4): Chemical Structure of Bisoprolol Fumarate. 
Indications: Treatment of high blood pressure (hypertension). Coronary heart disease 
(angina pectoris). 
Dosage:  One tablet a day. 
Price:  JD 5.64 (£4.80) per Pack, which contains 30 film-coated tablets. 
Manufacturer:  Merck (Germany).         
Thirty three samples of Concor were collected from Amman. These samples were subjected 
to physical as well as chemical analysis.  
Physical testing of Concor was conducted by visual inspection of the package. 
 
 Method of Analysis  
 The chemical analysis of Concor was performed by using high performance liquid 
chromatography for determination of bisoprolol assay as well as its related impurities.  
This item has been removed due to third party copyright. The 
unabridged version of the thesis can be viewed at the 
Lanchester Library, Coventry University. 
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The method used was from the United States Pharmacopoeia (USP), which was validated 
by the work performed by JPM in terms of linearity, the results indicate that this method is 
linear in the determination of bisoprolol fumarate in Concor tablets, the range between 
3.02-9.06 mg/100 ml, accurate, and precise. 
 
Standard and Sample Preparation for Analysis 
The buffer was prepared by dissolving  0.01M potassium dihyhdrogen phosphate in 1000ml 
water adding 0.1% v/v triethylamine, the pH was adjusted to 5.5 by 10% phosphoric acid.  
One Litre of mobile phase was prepared by using 570ml of the buffer and 430ml of 
methanol. 
For standard preparation: 50mg of bisoprolol fumarate working standard were weighed and 
dissolved in 50 ml water, then 3ml of this solution was diluted in 50 ml mobile phase. 
Sample preparation for assay and related: 20 tablets were weighed and powdered then an 
equivalent to 50 mg of bisoprolol fumarate was dispersed with 10 ml water and the volume 
was completed to 50 ml by adding mobile phase, then sonicated for 15 minutes, and 
centrifuged at 4000 rpm for 15 minutes, then the supernatant were used for related analysis, 
and for the assay analysis 3ml from this solution was diluted to 50ml with mobile phase. 
Diluted standard preparation: 50 mg of bisoprolol fumarate working standard were weighed 
and dissolved in 50ml water, 5ml of this solution was diluted to 50 ml with water, and 
further dilution of 5ml of this solution to 100ml with mobile phase was made. 
The high performance liquid chromatography (HPLC) apparatus consists of Thermo spectra 
system which is equipped with a pump (P 1000), an auto sampler spectra system (AS 
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3000), UV detector with a UV lamp, and data processor, the chromatographic column was 
Hypersil, BDS, C18, 5 µm, 250*4.6 mm. 
The detection wavelength used was 225nm, the flow rate was 1.0 ml/min, and the injection 
volume was 20µl. 
 
Calculations: Following are methods utilised in the calculation of assay and related 
impurities: 
Calculation for assay: Final Concentration (F.C) for the standard was calculated by the 
equation: 
(Standard weight/dilution)*(dilution factor)*(assay of the standard %)* (100-water content 
%)*100% 
Final Concentration for the Sample was calculated by the equation: 
Final concentration for the sample = (sample weight/dilution)* (dilution factor) *(tablet 
strength /tablet weight) * 100% 
Calculation for the assay of the sample was calculated by the equation: 
Assay for the sample % = (Average area for the sample /F.C. for the sample) *(F.C. 
standard) /average area for standard) *100% 
Calculation for the related impurities: 
Final Concentration for diluted standard was calculated by the equation: 
Final Concentration (diluted Standard) = (standard weight/ first dilution)* (dilution factor) 
* (assay for the standard %) * (100-content of water %) *100% 
Final Concentration for sample for related impurities was calculated by the equation: 
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Final concentration for related sample = (sample weigh/dilution) * (tablet strength/ tablet 
weight) * 100% 
Calculation for assay for maximum impurity was calculated by the equation: 
(Maximum impurity average area/ F.C. for the related sample) * (F.C for diluted standard/ 
average area for the diluted standard) *100% 
Calculation for total impurities was calculated by the equation: 
(Total impurities average area/ F.C. for the related sample) * (F.C for diluted standard/ 
average area for the diluted standard) *100% 
 
4.3.4 Lipitor Analysis 
Active Ingredients: Each tablet contains 21.69 mg. atorvastatin calcium. 
Chemical structure is shown in Figure (4.5) (USP 2011). 
 
Figure (4.5): Chemical Structure of Atorvastatin Calcium 
Indications: For reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, 
and triglycerides. 
Dosage:  The usual starting dose is 10mg. once a day; the maximum dose is 80mg. a day.  
This item has been removed due to third party copyright. 
The unabridged version of the thesis can be viewed at 
the Lanchester Library, Coventry University. 
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Price:  JD 47.68 (£ 40.75) per pack which contains 30 film-coated tablets. 
Manufacturer: Parke-Davis (Germany). 
Thirty three samples of Lipitor were collected and subjected to Physical and chemical tests. 
Chemical testing for Lipitor was conducted   using HPLC and an additional test called   
Dissolution testing.  
Physical testing of Lipitor was conducted by visual inspection of the package. 
 
1-Method of HPLC Analysis  
The analysis of Lipitor was performed by using high performance liquid chromatography 
for determination of atorvastatin calcium in Lipitor for assay as well as its related 
impurities. 
The method employed was from the United States Pharmacopoeia (USP),  which  was 
validated by the work performed by JPM in terms of linearity, the results indicate that this 
method is linear in determination of atorvastatin in Lipitor in the range between 5.00-15.01 
mg/100 ml, accurate within the same range, and precise. 
 
Standard and Sample Preparation for Analysis 
Mobile phase preparation: Phosphate buffer was prepared by weighing 6.8 gram of 
potassium dihydrogen phosphate and transferring it to 1000 ml of water, and adding 1 ml of 
triethylamine and the then the buffer is filtered through 0.45 µm membrane filter and 
degassed.  For mobile phase: a filtered and degassed mixture of phosphate buffer, 




For standard preparation 55 mg of atorvastatin calcium working standard was dissolved in 
50 ml methanol, 5 ml of this solution is diluted to 50 ml by adding a solution prepared with 
methanol and water in the ratio 1:1 which means 50% methanol. 
 Sample preparation for assay and related:  5 tablets were powdered and transferred into 
100 ml volumetric flask 10 ml of water was added to disperse then the volume completed 
with methanol, then sonicated for 30 minutes with frequent shaking and centrifuged at 4000 
rpm for 15 minutes, for related analysis the supernatants were used and for assay analysis 
further dilution is performed by diluting 5 ml of this solution to 50 ml with 50% methanol.  
Diluted standard preparation: 40 mg of atorvastatin calcium working standard were 
weighed and dissolved in 100 ml of methanol and 4 ml of this solution diluted to 100 ml 
with the same solvent. 
The high performance liquid chromatography (HPLC) apparatus consists of Thermo spectra 
system which is equipped with a pump (P 1000), an auto sampler spectra system (AS 
3000), UV detector with a UV lamp, and data processor. 
The chromatographic column was Hypersil, BDS, C18, 5µm, 250*4.6 mm. 
The detection wavelength used was 248 nm, the flow rate was 1.5 ml/min, and the injection 
volume was 20µl.  
 
Calculations: Following are methods utilised in the calculation of assay and related 
impurities: 




F.C. (standard) = (Standard weight/dilution)*(dilution factor)*2(558.65/1155.42) *(assay of 
the standard/100)* (100-water content/100)*100% 
(Where 558.65 and 1155.42 are the molecular weight of anhydrous atorvastatin and 
atorvastatin calcium respectively). 
Final Concentration for the Sample was calculated by the equation: 
 F.C. (sample) = (sample weigh /dilution)* (dilution factor) *(tablet strength) /tablet weigh) 
* 100% 
Calculation for the assay of the sample was calculated by the equation: 
Assay for the sample % = (Average area for the sample /F.C. for the sample) *(F.C. 
standard) /average area for standard) *100% 
Calculation for the related impurities: 
Final Concentration for diluted standard was calculated by the equation: 
F.C. (diluted Standard) = (standard weight/ first dilution) *(dilution factor) 
*2(558.65/1155.2) * (assay for the standard %) * (100-content of water %) *100% 
Final Concentration for sample for related impurities was calculated by the Equation: 
F.C. (sample) = (sample weight/dilution) * (tablet strength/ weight) * 100% 
Calculation for assay for maximum impurity was calculated by the equation: 
Max. Imp. % = (average area for the maximum impurity/ F.C. for the related sample) * 
(F.C for diluted standard/ average area for the diluted standard) *100% 
Calculation for total impurities was calculated by the equation: 
Tot. Imp. %= (total impurities average area/ F.C. for the related sample) * (F.C for diluted 




2- Lipitor Dissolution Analysis 
In order to evaluate the formulation effectiveness dissolution was performed on Lipitor 
since atrovastatin is poorly soluble and special care with formulation and manufacturing 
parameters is a must to insure atrovastatin tablets compliance to the required standards of 
solubility.  
 
 Method of Dissolution Analysis 
The method employed was from the United States Pharmacopoeia (USP),  which  was 
validated by the work performed by JPM in terms of linearity, the relation between the final 
concentration of atorvastatin and the first derivative response of solution is linear within the 
range 0.5-4.0 mg/100 ml, accurate within the same range, and precise. 
The method proved to be accurate, precise and could be used as alternative to the (USP) 
method. 
Buffer Preparation: the medium used was phosphate buffer which was prepared by 
dissolving 1.38 gram of sodium dihydrogen phosphate and 20 grams of dodecyl sodium 
phosphate in 900 ml water and pH was adjusted to 7.0 by adding 1M sodium hydroxide 
then the volume completed with water to 1000 ml.  
- Apparatus 2 (Paddle), 75 rpm. 
- Acceptable limit; not less than 80% Dissolved in 60 minutes. 
- Measure first Derivative. = 296 nm. 
- The standard was prepared by weighing and dissolving 120 mg.  Atorvastatin calcium 
working standard, in 100 ml methanol, and then diluted with 100 ml buffer. 
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For sample preparation: 6 tablets were introduced into the dissolution vessels, after 
60minutes a portion of the dissolution was centrifuged for 15 minutes at 4000 rpm, and the 
supernatant was  used for the analysis, the first derivative of these sample preparations and 
the standard preparation were measured at about 296 nm, scan speed was 1200nm/min. 
The apparatus used was Beckman Coulter (USA), Du 640i, and spectrophotometer.  
 
Calculations for Dissolution of Lipitor:  
Final Concentration of the standard was calculated by the equation: 
F.C. (standard) = (standard weight/dilution)*(dilution factor)*2(558.65/1155.42)* assay%* 
(100-content of water %)*100% 
A% standard = (average absorbency for standard /average F.C. standard)*1000 
Final concentration for the sample was calculated by the equation: 
(Sample strength / dilution)*100%. 
F.C. (sample) = (tablet strength /900)*100% 
Drug release of the sample = (average absorbency for sample/ average F.C. for sample)* 
(1/A %)* 100000. 
 
4.4 Analysis of Phase Two 
This phase consisted of forty samples of Concor which were collected from pharmacies 
from Amman, Irbid and Zarka. 
Concor was subjected to Physical and Chemical tests. The active material in the drug is 
bisoprolol fumarate. The analysis of Concor is performed using high performance liquid 
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chromatography for determination of bisoprolol assay as well as its related impurities as 
discussed in the analysis of Concor in phase one. 
 
4.5 Analysis of Known Counterfeit Samples 
Samples of counterfeit medicines were obtained from Jordan Food and Drug 
Administration (JFDA). According to (JFDA) officials, these samples were previously 
confiscated from different pharmacies. Medications obtained are: Plavix, Concor, and 
Lipitor, but Co-Diovan was not available. 
Physical appearance was inspected and chemical analysis was performed as follows: 
 
4.5.1 Plavix Analysis: Two samples were obtained and were subjected to physical and 
chemical analysis. 
Physical testing of Plavix included visual inspection of the packages. 
The chemical analysis of Plavix (clopidogrel) tablets was performed using high 
performance liquid chromatography for assay and related impurities. The method used was 
validated and employed as discussed in the analysis of Plavix in phase one.   
 
4.5.2Lipitor Analysis: Two samples were obtained from the Jordan Food and Drug 
Administration (JFDA), the customs authority previously confiscated one and the other one 
was confiscated from the market. These samples were subjected to three tests: 
Physical, chemical, which included HPLC and dissolution testing. 
Physical testing of Lipitor included visual inspection of the packages. 
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The chemical analysis methods were validated and employed as discussed in the analysis 
used for Lipitor in phase one. 
 
4.5.3 Concor Analysis 
One sample obtained from Jordan Food and Drug Administration (JFDA), which was 
previously confiscated from the market. This sample was subjected to physical and 
chemical analyses.  The physical testing including visual inspection of the package. 
The active material in the drug is bisoprolol fumarate. The chemical analysis of Concor is 
performed by using high performance liquid chromatography for assay and related 
impurities. The method used was from the United States Pharmacopoeia (USP), which was 
modified and validated before applicationas discussed in the analysis of Concor in phase 
one. 
 
4.6 Identification Analysis for the Samples of Known Counterfeit Medications 
The following tests are considered as useful in identifying counterfeit pharmaceuticals 
since other possible tests for minor excipients would not be as discriminating as these tests.  
Therefore further analysis for the identification of the ingredients was performed as 
follows: 
Concor average weight ranges from   136.8 mg to 139.4 mg. 
 Lipitor average weight ranges from 288 mg to 307 mg.  





4.6.1 Identification of Starch 
Using the British Pharmacopoeia, 10 tablets were powdered, one gram of the powder was 
put in a flask and 50 ml of water were added and boiled for one minute then cooled. The 
result was thick, gluey and cloudy solution 0.05 ml of iodine solution was added to 1ml of 
the mucilage. The result was an orange-red to dark blue colour which is an indication of the 
presence of starch in the formula which disappears on heating. 
 
4.6.2   Identification of Lactose: British Pharmacopoeia method was used to identify the 
existence of lactose in the formula.   
10 tablets from the original and counterfeit samples were powdered and 0.25 gram was 
added to 5 ml of water and 5 ml of ammonia. The mixture was heated in a water-bath at 80 
C for 10 minutes.  
If the lactose is present in the formula, a red colour develops.  
 
4.6.3 Identification of Hydroxypropylcellulose: British Pharmacopoeia method was used 
to identify the existence of hydroxypropylcellulose in the formula.   
10 tablets were powdered and one gram of the powder was added into 50 gram of carbon 
dioxide-free water, then the mixture was heated to 90 C and allowed to cool, then adjusted 
to100 gram with carbon dioxide-free water, and stirred until dissolution is completed. 
10ml of solution, 0.3 ml of diluted acetic acid, and 2.5ml of a 100 gram solution of tannic 
acid were added together.   
If the hydroxypropylcellulose exists then a yellowish-white flocculent precipitate is formed 




















5. Results of Known Counterfeit Pharmaceuticals 
Samples of counterfeit medicines were obtained from Jordan Food and Drug 
Administration (JFDA). According to (JFDA) officials, these samples were previously 
confiscated from different pharmacies. Medications obtained are Plavix, Concor and 
Lipitor, while Co-Diovan was not available.  
Physical appearance was inspected and chemical analysis was performed as described in 
chapter 4, and following are the results. 
 
5.1 Results of Analysis of Known Counterfeit Plavix 
Two samples were obtained and subjected to physical and chemical analysis. 
 
5.1.1 Results of Physical Testing:  Visual inspection showed that both packages have the 
same batch number but different expiry dates.  The packaging for each sample is almost the 
same as the genuine medicine except that one of the counterfeit samples had different 
colour from the genuine one. Both counterfeit samples have no hologram as shown in 
figure (5.1).  
The letters on the packages have the same font size and colour.  It was obvious that the 
technology used in manufacturing of the final packaging is high technology and the 
counterfeiters put a lot of effort trying to imitate the colour, size, and everything related to 
the final production of the product in order to deceive the public as well as the authority by 
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duplicating the original packaging. Even the batch number of the counterfeit samples has 
four digits numbers the same as the original sample. 
 
 
Figure (5.1): A Comparison between Genuine and Counterfeit Plavix 
(The genuine medicine is on the top while the counterfeit one is on the bottom) 
 
Looking at blisters, there seems to be no differences except that the font used in the 
counterfeit drug was a little bit larger than the one used in the genuine medicine, as shown 




Figure (5.2): A Comparison between Genuine Blister and Counterfeit Blister of Plavix 
(Blisters of the genuine medicine on the top and the counterfeit one on the bottom) 
 
Test on tablets was performed by weighing the counterfeit tablets and the original ones 
and comparing the shape, color, and the size of the counterfeit tablets and the original 
ones, as shown in figure (5.3).  
 
Figure (5.3): A Comparison between Genuine and Counterfeit Plavix tablets 





As shown in figure (5.3), one counterfeit tablet sample D200 has a different colour from the 
original. It was noticed that, the counterfeit tablet D 200 was hard to powder and when it 
was crushed, the powder turned to granules. The range of the weight of the tablets was 250 
mg to 257 mg compared to the range of the original, which was between252 mg and 256.9 
mg for each tablet which constitutes a slight difference  but not statistically significant. 
The other sample (D201) which looks like the original, but when powdered, it looks like 
granules not powder, and the tablets weigh more than the genuine one  with wide range 
from 270 mg to 280 mg. 
 
5.1.2 Results of Chemical Analysis 
A result of Chemical analysis of the confiscated samples of Plavix which was obtained 













90%≤ Assay limit ≤110%. Impurity A ≤ 1.2% 
Impurity C ≤ 1.5% 
 
Table (5.1):  Results of Assay and Related Impurities Testing of Counterfeit Plavix. 








As shown in table (5.1) results indicated that D201 sample has zero active ingredients 
the sample labeled D200 , s shown in Table (5.1),clopidogrel related  ((S)-(ochlorophenyl)-
6,7-dihydrothieno[3,2-c] pyridine5(4H)-acetic acid, Hydrochloride. Chemical structure is 













 A % 
Impurity 
 C % 
Plavix  
original 
2359 4-2008 4-2011 101.7 0.05 0.49 
Plavix D200 1476 01-2005 01-2008 4.6 0 0 






Figure (5.4) Chemical Structure of Clopidogrel Related Impurity A. 
and Related impurities  achiral isomer of clopidogrel named as clopidogrel related 
compound C is  Methyl(-)-R-(ochlorophenyl)-6,7-dihydrodtheino [3,2-c] pyridine-5(4H)- 
acetate, hydrogen sulphate. Chemical structure is shown in figure (5.5) (Mohan et al. 2008). 
Figure (5.5) Chemical Structure of Clopidogrel Related Impurity C. 
Comparison between genuine and counterfeit samples of Plavix 
Figure (5.6) shows the HPLC chromatogram of genuine Plavix and figures (5.7) and (5.8) 
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Figure (5.6): HPLC Chromatogram Showing the Active Ingredient (Clopidogrel) in 
the Original Medicine 
 
As indicated in the figure above, the retention time for the active ingredient (clopidogrel) is 
around 6 minutes. 





Figure (5.7)  Counterfeit Medicine Coded D200. 
The figure indicates that a very small amount of the active  ingredeintis noticed as indicted 
by the retension time which is  around 6 minutes for the original while unknown peak was 
noticed at around 2 minutes. 
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Figure (5.8):  Counterfeit Medicine coded D201. 
The  chromatograms of the counterfeit sample (D201) as shown in the figureis not 
colpedogril as indicted  by the retention time. There is no peak around 6 minutes retention 
time.  
HPLC chemical analysis indicated that there was no active ingredient found in D201 and 
only4.6% active ingredient found in D200 which is supposed to be not less than 90% in this 
medicine which is widely used in Jordan in artery operations as post operation medication 
to prevent depositions in arteries. 
 
5.2 Results of Analysis of Known Counterfeit Lipitor 
Two samples of Lipitor were obtained from the Jordan Food and Drug Administration 
(JFDA), one was confiscated by the customs authority and the other was confiscated from a 




5.2.1 Results of Physical Testing: Visual inspection of the packages showed that the two 
samples have different batch numbers with different expiry dates.  Inspecting batch 
numbers of both counterfeit samples indicated that they have the same seven digits format, 
which is the same digit as the original one.  
The packaging of counterfeit sample looks the same as the genuine one; even the colour of 
the printing and the font size of the printing is the same as the genuine packaging.  The 
shape and the color of the counterfeit tablets are almost the same as the genuine medicine 
which makes it hard to distinguish between the counterfeit and the original medicine, as 
shown in figure (5.9). 
 
Figure (5.9): A Comparison between Genuine and Known Counterfeit Lipitor 
(The genuine medicine on the right and the known counterfeit one on the left). 
 
Inspecting the blisters of the counterfeit medicines indicated that it was very hard to 




Figure (5.10): A Comparison between Genuine and Known Counterfeit Blisters of 
Lipitor. 
(The genuine blister on the left, the known counterfeit blister on the right). 
 
As shown in figure (5.11), the colour, size and shape of the counterfeited tablets were the 
same as the original ones. It also showed that, the weight of the counterfeit tablet ranged 
from 276 to 288 mg which is significantly less than the genuine one  (303 to 318 mg). The 
weight of the second sample of counterfeit drug was between 288 to 307 mg, which is 





Figure (5.11): A comparison between Genuine and Known Counterfeit Lipitor Tablets 
(The genuine tablet is on the right and the known counterfeit tablets are on the left). 
 
The physical appearance of the confiscated samples obtained from (JFDA) looks like the 
original package.  This fact made it harder for the authority to distinguish the counterfeit 
from the original pharmaceutical. This result confirms the fact that counterfeiters usually 
utilise very sophisticated technology for manufacturing and packaging. The counterfeiters 
pay a great attention to the details of the outer package in an attempt to deceive consumers, 
the authority and any buyers into believing that these products are original, so the printing 
font size and colour of the package and the printing is imitated exactly.   
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5.2.2 Results of Chemical Analysis of Lipitor 
Lipitor was subjected to two chemical analyses: 
Results of HPLC Analysis:  HPLC analysis of Lipitor is shown in table (5.2). 
Table (5.2):  Results of Assay and Related Impurities Testing of Known Counterfeit 
Lipitor (20mg). 

















0330088 3-2008 2-2011 99.1 0.26 0.65 
Lipitor 
B200 
0359045 04-2005 03-2008 73.59 0.11 1.94 
Lipitor 
201 
0195036 03-2006 02-2009 72.49 0.30 0.67 
 
Table (5.2) shows a comparison between the active ingredient amount in both the genuine 
and the counterfeit Lipitor. It shows that the samples contain the active ingredients but with 
quantities below the pharmacopoeial limits which classifies these samples as substandard 
products. It was noticed that the counterfeit sample (B200) has an amount of active 
ingredient of (73.59%) and B201 has the amount of (72.49%) while the original medicine 
has (99.1%) as depicted in the following figures. 
90%≤ Assay limit ≤110%. Maximum Impurity ≤ 1.5% 
Total Impurities ≤   3.5% 
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The related impurities in Lipitor are Atorvastatin amide, Desfluoro Atorvastatin, 
Diastereoisomer, O-methyl Atorvastatin, Atorvastatin lactone and Atorvastatin methyl 

















Figure (5.14): HPLC Chromatogram of Known Counterfeit Lipitor Coded B201 
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The above three figures indicated that the retention time and the UV-absorption recorded 
on the peak indicate that the active ingredient is atorvastatin but the quantity of the active 
ingredient was different from the original as noticed by the height of the peaks. This is a 
typical example of counterfeit medicine characterised by wrong quantity of active 
ingredients. This sample failed the specification in terms of content, which is less than the 
acceptable limits noticed by the (HPLC) analysis, as shown in the figures 5.12– 5.14. 
 
Results of Dissolution Analysis  
In order to evaluate the formulation effectiveness, a dissolution test was performed on 
Lipitor since atorvastatin is poorly soluble and special care with formulation and 
manufacturing parameters is required to insure atorvastatin tablets compliance with the 
required standards of solubility.   
 Dissolution test is frequently used to measure the stability of the drug. It measures the 
amount of the drug available to the body (bioavailability). In this sense dissolution test is a 
quality control test which the drug must pass in order to be authorized for use in the market.   
As shown above there are differences between the two samples. The two samples were 
analysed for their drug release and the results are in table 5.3. 
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% Drug Release Limit ≥ %80 
Table (5.3): Results of Dissolution Testing of Known Counterfeit Lipitor (20mg) 
 
 
Sample ID Batch No. Manuf. Date Expiry Date %Drug Release 
Lipitor Gen. 0330038 3-2008 2-2011 101.6% 
Lipitor B200 0359045 04-2005 03-2008 79.145% 
Lipitor B201 0195036 03-2006 02-2009 29.714% 
 
Dissolution tests have shown a large non- controlled practice for one of the samples (B201) 
as shown in table (5.3) where the percentage of the drug release was 29.7%, which is below 
the pharmacopoeial limit of 80%. This illustrates the tendency of counterfeiters to pay great 
attention to the appearance of the final product. 
Results on the other hand, have indicated that sample (B200) as shown in table (5.3) has a 
much lower degree of bioavailability since drug release was below the pharmacopoeial 
limits of only one percent. These results indicate that two different manufacturers produced 
the two batches. 
In summary, dissolution tests for Lipitor seem to indicate a large variability in the process, 
which ranges from simply a substandard to a completely counterfeited pharmaceutical in 




Sample 1: (B200) showed less than the acceptable percentage limit of drug release79.145% 
which was slightly lower than the United States Pharmacopoeia  limit and old  expiry date 
which made it close to original (80% or over). 
Sample 2: (B201) showed a very poor dissolution profile and a very low release percentage 
of active ingredients 29.7%.These results may be attributed to the formulation employed 
and/or to the storage conditions.  
Dissolution tests indicate large non- controlled practice for one of the samples (B201). The 
other sample only has an assay value of 73.6% and has a percentage release of 79.1% 
compared with the claimed figure. Although B200 may be less than ideal if consumed by a 
patient, B201 would be far worse as the patient would receive very little active drug. 
 
5.3 Results of Analysis of Known Counterfeit Concor 
One sample was subjected to physical and chemical analysis. 
 
5.3.1 Results of Physical Testing: Visual inspection of the package showed that the known 
counterfeit package looks exactly as the original package. As seen in figure (5.15) the 
package has the same size and the printing colour and the same font size of printing as the 





Figure (5.15): A Comparison between Genuine and known Counterfeit Concor 
( The genuine medicine on the top and the known counterfeit on the bottom). 
 
It was obvious that the counterfeiters paid a lot of attention to the very specific details on 
the outer package, the font size printing, the colour of the package, and the logo of the 
manufacturing company using high technology to imitate these products. The only 
difference noticed was that genuine Concor has a six digit batch number while the 
counterfeit package has seven digits. 
The shape of the tablets has a heart-shaped form which is usually hard to imitate without 
very specialised tools. When crushing the tablets for the analysis, the researcher noticed 
that crushing was very hard and the final powder is granular unlike the original powder. In 
addition, original tablets have white colored powder while the counterfeited ones were 
yellow. When weighing the tablets, the counterfeit tablets weighed less than the original 
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tablets. Their weight ranges from   136.8 mg to 139.4 mg while the original weighs 171mg 
to 173.9 mg. The colour, size and shape of the tablets was also compared and found to have 
the same as the original 
The colour and shape of the tablets is shown in figure (5.16) 
 
Figure (5.16): A Comparison between Genuine and Known Counterfeit Concor 
tablets 
(The genuine tablet is on the right and the known counterfeit tablet on the left) 
 
5.3.2 Results of Chemical Analysis of Concor 
Chemical analysis showed no active ingredients available in A200 as shown in   table (5.4). 
This result indicates a very serious problem for the patients who think that their blood 
pressure is actually being regulated by taking these zero active ingredient pharmaceuticals 
Table (5.4) shows a comparison between the active ingredient amount in both the genuine 
and the counterfeit Concor.  
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90%≤ Assay limit ≤110%. 
Max. Impurity ≤0.25% 
Total Impurities ≤   1.0% 
Table (5.4):  Results of Assay and Related Impurities Testing of Known Counterfeit 
Concor 

















101071 2-2009 1-2012 99.5 0.03 0.11 
Concor 
A200 
3723703 09-2006 08-2009 0 0 0 
 
As shown in table (5.4) there is no active ingredient in the sample obtained from (JFDA). 
Figures (5.17) and (5.18) show a comparison between (HPLC) chromatogram regarding  













Figure (5.17): HPLC Chromatogram showing the active ingredient (Bisoprolol 
Fumarate) of the Genuine Medicine. 
 
Figure (5.17) illustrates the existence of the active ingredients in the genuine Concor 
(bisoprolol fumarate) in the second peak; while figure (5.18) shows that there is no active 
ingredient in the counterfeited medicine. Instead, there are two un- identified peaks 





Figure (5.18):  HPLC Chromatogram of the Known Counterfeit Medicine. 
The related impurities for concor are Bisoprolol Dibenzylether, Bisoprolol n-propoxy-
isomer, Bisoprolol derivative Diphenyl methane, Bisoprolol Benzylalcohol and Bisoprolol 
derivative Z/E-olefin (USP 2006). 
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The  chromatogram of the counterfeit sample indicated  that it contains the wrong 
ingredeint. The substance presented in this  sample is not Bisoprolol, as shown by the 
retention time of the original sample. There is no peak around 10 minuts retention time.  
Therefore, after conducting the (HPLC) analysis, the sample was classified as counterfeit 
based on the absence of the active ingredient (bisoprolol fumarate) in the sample. 
 
5.4 Results of Identification Analysis for the Samples of Known Counterfeit 
Medications 
The following tests are considered as useful in identifying counterfeit pharmaceuticals 
since other possible tests for minor excipients would not be as discriminating as these tests.  















5.4.1 Results of Identification of Starch  
The results are presented in table (5.5). 
Table (5.5): Results of Starch Identification in the Original and Known Counterfeit 
Samples. 
Sample ID Colour Contain starch 
Lipitor original Light brown No 
Lipitor B200 Light brown No 
Lipitor B201 Orange-red to dark blue yes 
Plavix Original Light brown No 
Plavix D200 Orange-red to dark blue Yes 
Plavix D201 Orange-red to dark blue Yes 
Concor Original Orange-red to dark blue Yes 
Concor A200 Orange-red to dark blue Yes 
 
As shown in Table (5.5) Lipitor B201 contains starch, a component that does not exist in 
non-counterfeited Lipitor. 
For Plavix, results of analysis in Table (5.5) indicated that the original sample does not 
contain starch while the two counterfeited samples do contain starch. 
Finally, results indicated that Concor has starch in both original and the counterfeit 
samples. 
These results confirm what has been found in previous studies that most counterfeited 
drugs contain starch instead of active ingredients and other excipeints that should be found 





5.4.2   Results of Identification of Lactose 
The results are presented in table (5.6). 
Table (5.6): Results of Lactose Identification in the Original and Known Counterfeit 
Samples. 
Sample ID Colour Lactose 
Lipitor Original red Yes 
Lipitor B200 Pink to red Yes 
Lipitor B201 white No 
Plavix Original white No 
Plavix D200 white No 
Plavix D201 white No 
Concor Original White No 
Concor A200 white No 
 
The results of the analysis as shown in table (5.6) indicted that among all samples used in 
this analysis, only Lipitor original and b200 have lactose. 
 
5.4.3 Results of Identification of Hydroxypropylcellulose: British Pharmacopoeia 
method was used to identify the existence of hydroxypropylcellulose in the formula.   







Table (5.7):  Results of Hydroxypropylcellose Identification in the Original and 
Known Counterfeit Samples. 
Sample ID Colour 
Existence of 
Hydroxypropylcellulose 
Lipitor Original Yellowish-white Yes 
Lipitor  B200 Yellowish-white Yes 
Lipitor  B201 Yellowish-orange No 
Plavix Original Yellowish-white Yes 
Plavix D200 Yellowish-orange No 
Plavix D201 Yellowish-orange No 
Concor Original Yellowish-orange No 
Concor A200 Yellowish-orange No 
 
As shown in table (5.7) Lipitor original and B200, the yellowish- white flocculent colour 
was noticed but for B201 there is no trace of hydroxpropylcellulose. 
In Plavix samples, only the original sample indicated the presence of hydroxypropylcell-
ulose. 










5.5Summary of the Results of Known Counterfeit Samples 
The above analysis revealed that, the counterfeited drug has characteristics different from 
the genuine one. Some of the counterfeited drug has no active ingredients at all, while some 
others have some active ingredients significantly below the pharmacopoeial limits. 
These results indicated that the (HPLC) analysis can successfully differentiate counterfeit 
from non-counterfeit medicines. 
Further analysis of Plavix confirmed that it contains starch while the original non-
counterfeited Plavix has no starch.  The price of active material is many times higher than 
the price of starch.  
This finding confirms the fact that counterfeiters usually use starch instead of active 
ingredients. This is a typical example of counterfeit medicine characterised by wrong active 






























6. Results of Phase One (AMMAN) Survey Test Sample 
This chapter presents the results of the analysis of phase one 
 
6.1 Results of Testing Analysis 
Following are the results of all tested samples: 
 
6.1.1 Results of Co-Diovan Analysis  
Co-Diovan was subjected to two tests: 
 
 Results of Physical Testing Physical testing of Co-Diovan included visual inspection of 
the package.  It was found that all samples that obtained from different pharmacies have the 
same packaging as the original package, the font size printing, the colour of the package, 
the logo of the manufacturing company are all similar to the original packaging. The tablets 
were weighed and compared to the weight of the original, which were ranged from 306 mg 
to312.8 mg for each tablet.   It was also noticed that all the tablets weights were found 
within the range, with same colour, size and shape of the original tablets. 
 
 Results of Chemical Analysis 
The analysis of Co-Diovan was performed by using high performance liquid 
chromatography for the determination of valsartan/ hydrochlorothiazide assay as well as its 
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related impurities. Thirty three samples of Co-Diovan were analysed for their assay and 
related impurities as shown below. 
All Co- Diovan samples were coded with the letter C. Table (6.1) shows the results of assay 
testing of Co-Diovan. 
Table (6.1):  Results of Assay Testing of Co-Diovan 
USP acceptance limits for Co-Diovan are given in the boxes overleaf. 
 














C1 S0425 7-2008 6-2011 96.8 99.5 
C2 S0425 7-2008 6-2011 98.4 100.9 
C3 S0390 4-2008 3-2011 96.8 100.2 
C4 S0425 7-2008 6-2011 97.6 100.6 
C5 S0425 7-2008 6-2011 97.2 100.3 
C6 S0425 7-2008 6-2011 98.4 101.8 
C7 S0425A 7-2008 6-2011 98.8 102.6 
C8 S0390 4-2008 3-2011 97.7 100.4 
C9 S0390 4-2008 3-2011 99.2 101.9 
C10 S0425 7-2008 6-2011 98.2 101.8 
C11 S0425 7-2008 6-2011 97.1 103.6 
C12 S0425 7-2008 6-2011 95.7 102.5 
C13 S0425 7-2008 6-2011 100.3 102.3 















C15 S0425 7-2008 6-2011 96.6 103.0 
C16 S0390 4-2008 3-2011 97.5 103.8 
C17 S0425 7-2008 6-2011 96.6 102.1 
C18 S0425 7-2008 6-2011 96.9 99.4 
C19 S0425 7-2008 6-2011 97.0 102.3 
C20 S0425 7-2008 8-2011 95.4 102.3 
C21 S0295 11-2007 10-2010 96.8 103.7 
C22 S0425A 7-2008 6-2011 99.4 100.7 
C23 S0425 7-2008 6-2011 100.0 101.0 
C24 S0313 12-2007 11-2010 100.1 101.0 
C25 S0491 4-2009 3-2012 103.0 104.2 
C26 S0425 7-2008 6-2011 101.7 104.4 
C27 S0390 4-2008 3-2011 98.3 102.5 
C28 S0313 12-2007 11-2010 102.3 105.6 
C29 S0425 7-2008 8-2011 98.5 101.5 
C30 S0491 4-2009 3-2012 99.2 101.2 
C31 S0355 3-2008 2-2011 99.8 100.8 
C32 S0390 4-2008 3-2011 97.7 102.6 
C33 S0425 7-2008 8-2011 99.9 103.4 
 
 
Results of Co-Diovan analysis shown in table (6.1) indicated that all samples have contents 
within acceptable limits ranging between 90 – 110 percent. 
The only note that should be mentioned here is that batches numbers C7and C22 have been 
followed with a letter A. This showed a different pattern, which might indicate that when 
changing the batch number; the possibility of this situation being exploiting by 
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Impurity A ≤ 1.0% 
Any Impurity ≤ 0.2% 
Total Impurities   ≤   1.3% 
 
counterfeiters is increased. More likely, this has been a repackaging operation i.e. the single 
batch of drug capsules has been re-blistering packed and re-boxed for another generic 
distributor and hence the batch number has recognised this by the addition of an A to the 
end of the batch number. 
Table (6.2) shows the results of related impurities for Co-Diovan. 
Table (6.2): Results of Related Impurities Testing of Co-Diovan 


















C1 0.03 0.01 0.01 0.05 
C2 0.03 0.01 0.01 0.05 
C3 0.03 0 0.02 0.05 
C4 0.03 0.02 0.03 0.08 
C5 0.03 0.03 0.03 0.09 
C6 0.03 0.02 0.04 0.09 
C7 0.03 0.02 0.03 0.08 
C8 0 0 0 0 
C9 0.01 0.01 0.01 0.03 
C10 0.03 0.01 0.01 0.05 















C12 0.05 0.04 0.01 0.10 
C13 0.04 0.07 0.01 0.13 
C14 0.05 0.05 0.01 0.11 
C15 0.05 0.05 0.01 0.11 
C16 0.02 0.03 0.01 0.06 
C17 0.04 0.05 0.01 0.12 
C18 0.04 0.06 0.01 0.11 
C19 0.05 0.07 0.01 0.13 
C20 0.05 0.03 0.01 0.09 
C21 0.05 0.03 0.01 0.10 
C22 0.04 0.04 0.01 0.09 
C23 0.04 0.05 0.01 0.10 
C24 0.06 0.05 0.02 0.13 
C25 0.06 0.06 0.02 0.14 
C26 0.05 0.05 0.01 0.11 
C27 0.04 0.03 0.02 0.09 
C28 0.04 0.04 0.01 0.09 
C29 0.04 0.06 0.01 0.11 
C30 0.05 0.04 0.01 0.10 
C31 0.04 0.05 0.01 0.10 
C32 0.05 0.06 0.01 0.12 
C33 0.05 0.06 0.01 0.12 
 
Co-Diovan related impurities analyses as shown in table (6.2) indicated that all samples 









Figure (6.1): Chromatograph for Assay and Related Impurities for Co-Diovan 
 
Results of Co-Diovan analyses indicated that no unknown peaks were observed and all 
samples were shown content within acceptable limits. 
All samples analysed were within the pharmacopoeial limits and are considered safe 
pharmaceuticals.  
Impurity A is for Benzothiadiazine related compound A not more than 1%,  valsartan 
related compound A (S)-N-butyryl-N-((2-(1H-tetrazole-5-yl)-biphenyl-4-yl)-methyl1)-
valine.(Ivanovic, Malenovic and Jancic 2007), the unknown impurities “any other 
impurity” was found less than0.2% which is the acceptable limit. The total impurities were 
found less than 1.3% which indicates that the related impurities analyses as shown in table 
(6.1) were within acceptable limits. Based on the findings it was concluded that there is no 





6.1.2 Results of Plavix Analysis 
Plavix was subjected to two tests: 
 
Results of Physical Testing 
Physical testing of Plavix included visual inspection of the package.  It was found that all 
samples that obtained from different pharmacies have the same packaging as the original 
package including the font size printing, the colour of the package, and the logo of the 
manufacturing company are all similar to the original packaging. The tablets were weighed 
and compared to the weight of the original which was ranged from (252 mg to256.9 mg) 
for each tablet.   It was also noticed that all the tablets weights were found within the range, 
and have the same colour, size and shape of the original tablets. 
 
Results of Chemical Analysis  
The chemical analysis of Plavix was performed by using high performance liquid 
chromatography for the determination of clopidogrel assay as well as its related impurities. 
Thirty three samples of Plavix were analysed. All Plavix samples were coded with the letter 









Table (6.3):  Results of Assay and Related Impurities Testing of Plavix. 






















D1 2359 4-2008 4-2011 100.6 0.05 0.43 0.50 
D2 2359 4-2008 4-2011 98.9 0.08 0.46 0.57 
D3 2241 10-2007 10-2010 98.8 0.09 0.74 0.87 
D4 2129 12-2006 12-2009 99.5 0.07 0.94 1.04 
D5 2359 4-2008 4-2011 98.6 0.06 0.51 0.61 
D6 2323 2-2008 2-2011 99.4 0.07 0.91 0.99 
D7 2359 4-2008 4-2011 99.0 0.12 0.31 0.45 
D8 2359 4-2008 4-2011 98.4 0.15 0.39 0.55 
D9 2359 4-2008 4-2011 99.1 0.15 0.40 0.58 
D10 2359 4-2008 4-2011 100.4 0.15 0.41 0.58 
D11 2424 9-2008 9-2011 97.0 0.03 0.78 0.85 
D12 2359 4-2008 4-2011 96.0 0.04 0.72 0.80 
D13 2359 4-2008 4-2011 97.5 0.04 0.74 0.81 
D14 2424 9-2008 9-2011 97.3 0.04 0.83 0.91 
D15 2359 4-2008 4-2011 96.1 0.04 0.78 0.86 
D16 2359 4-2008 4-2011 97.7 0.05 0.78 0.84 
D17 2359 4-2008 4-2011 Ii97.7 0.04 0.75 0.83 
D18 2359 4-2008 4-2011 94.8 0.04 0.76 0.84 
D19 2359 4-2008 4-2011 96.1 0.04 0.80 0.87 
D20 2359 4-2008 4-2011 96.9 0.06 0.79 0.86 
90%≤ Assay limit ≤110%. 
 Impurity A ≤ 1.2%    Total Impurities ≤ 2.5 






















D21 2424 9-2008 9-2011 96.9 0.05 0.86 0.92 
D22 2241 10-2007 10-2010 96.1 0.05 1.13 1.21 
D23 2490 11-2008 11-2011 102.6 0.05 0.60 0.64 
D24 2490 11-2008 11-2011 102.0 0.05 0.69 0.77 
D25 2359 4-2008 4-2011 101.7 0.05 0.49 0.54 
D26 2424 9-2008 9-2011 103.4 0.03 0.35 0.39 
D27 2241 10-2007 10-2010 102.6 0.01 0.49 0.50 
D28 2273 1-2008 1-2011 99.4 0.04 0.92 0.99 
D29 2490 11-2008 11-2011 99.7 0.02 0.54 0.67 
D30 2490 11-2008 11-2011 101.7 0.03 0.63 0.69 
D31 2424 9-2008 9-2011 102.0 0.02 0.41 0.43 
D32 2490 11-2008 11-2011 102.6 0.04 0.36 0.40 
D33 2359 4-2008 4-2011 101.7 0 0.41 0.41 
 
 
Plavix assay and related impurities analysis as shown in table (6.3) which indicated that  the 
typical content of active pharmaceutical ingredients (API)  was between (96.0-103.4%) 
while the acceptable limits ranging from 90-110%. This means that all samples analysed 
were within the pharmacopoeial limits and are considered safe pharmaceuticals. As for the 
related impurities, clopidogrel related impurity A is ((S)-(ochlorophenyl)-6, 
7-dihydrothieno[3,2-c] pyridine5(4H)-acetic acid, Hydrochloride  was found less than 1.2% 
which is within the acceptable limits and related impurities  a chiral isomer of clopidogrel 
named as clopidogrel related compound C is  (-)-R-(ochlorophenyl)-6,7-dihydrodtheino 




While total impurities were found less than 2.5% which indicates that the related impurities 
analyses as shown in table (6.3) were within acceptable limits. Based on these  









Figure (6.2): Chromatograph for Plavix Assay. 
 
Figure (6.2) shows the chromatograph for Plavix assay. It shows that the retention time 
and the UV-absorption spectrum shown in figure 6.2 indicated that the sample is Plavix and 
no unknown peaks were observed. 





Figure (6.3): Chromatograph for Related Impurities for Plavix 
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6.1.3 Results of Concor Analysis 
Concor was subjected to two tests: 
 Results of Physical Testing 
Physical testing of Concor included visual inspection of the package. It was found that all 
samples that obtained from different pharmacies from (Amman, Irbid and Zarqa) have the 
same packaging as the original sample, and the font size printing, the colour of the package, 
and the logo of the manufacturing company are all similar to the original packaging. The 
tablets were weighted and compared to the weight of the original which was ranged from 
171 mg to 173.9 mg for each tablet. It was also noticed that all the tablets weights were 
found within the range, the colour, size and shape of the original. 
 
Results of Chemical Analysis 
The chemical analysis of Concor was performed by using high performance liquid 
chromatography for the determination of bisoprolol assay as well as its related impurities. 
Thirty three samples of Concor were analysed. All Concor samples were coded with the 










Table (6.4):  Results of Assay and Related Impurities Testing of Concor 

















A1 5787901 8-2008 7-2011 97.4 0.04 0.16 
A2 5787901 8-2008 7-2011 96.5 0.04 0.16 
A3 5508101 11-2007 10-2010 97.5 0.07 0.26 
A4 5707301 6-2008 5-2011 99.1 0.04 0.16 
A5 5788501 8-2008 7-2011 98.9 0.07 0.13 
A6 5787901 8-2008 7-2011 98.0 0.06 0.20 
A7 5787901 8-2008 7-2011 98.2 0.07 0.13 
A8 5787901 8-2008 7-2011 99.6 0.06 0.15 
A9 5787901 8-2008 7-2011 100.4 0.07 0.18 
A10 5787901 8-2008 7-2011 101.0 0.07 0.16 
A11 100536 11-2008 10-2011 100.2 0.05 0.17 
A12 100536 11-2008 10-2011 97.9 0.05 0.17 
A13 5787901 8-2008 7-2011 98.4 0.05 0.20 
A14 5787901 8-2008 7-2011 98.2 0.05 0.13 
A15 100536 11-2008 10-2011 98.8 0.05 0.08 
A16 100536 11-2008 10-2011 97.7 0.04 0.12 
90%≤ Assay limit ≤110%. 
Max. Impurity ≤0.25% 

















A17 101071 2-2009 1-2012 101.3 0.03 0.13 
A18 100536 11-2008 10-2011 98.5 0.05 0.09 
A19 101071 2-2009 1-2012 99.7 0.05 0.16 
A20 101071 2-2009 1-2012 99.5 0.03 0.11 
A21 5508101 11-2007 10-2010 102.7 0.05 0.19 
A22 101071 2-2009 1-2012 97.6 0.05 0.17 
A23 5507403 11-2007 10-2010 96.6 0.08 0.27 
A24 101071 2-2009 1-2012 97.9 0.09 0.25 
A25 101071 2-2009 1-2012 98.4 0.09 0.28 
A26 101759 5-2009 2-2012 98.2 0.08 0.24 
A27 101071 2-2009 1-2012 97.5 0.06 0.18 
A28 101071 2-2009 1-2012 97.4 0.08 0.16 
A29 101071 2-2009 1-2012 97.2 0.04 0.12 
A30 101071 2-2009 1-2012 97.2 0.05 0.13 
A31 101071 2-2009 1-2012 97.8 0.05 0.13 
A32 5787901 8-2008 7-2011 96.6 0.08 0.29 









Figure (6.4): Chromatograph of Assay for Concor 
 
Figure (6.4) shows chromatograph of assay for Concor. It shows that the retention time 
The UV-absorption spectrum shown in Figure 6.4 indicated that the sample is Concor, the 
first peak is for fumaric acid and the second peak is bisoprolol which is the active 
ingredient in Concor and no unknown peaks were observed. 
Figure (6.5) shows the chromatograph for related impurities of Concor.  The related 
impurities for concor are Bisoprolol Dibenzylether, Bisoprolol n-propoxy-isomer, 
Bisoprolol derivative Diphenylmethane, Bisoprolol Benzylalcohol and Bisoprolol 














Figure (6.5): Chromatograph for Related Impurities of Concor. 
Results of Concor analyses indicated that all samples were shown to have content within 
acceptable limits. 
 
6.1.4 Results of Lipitor Analysis 
Lipitor was subjected to three tests: 
 
Results of Physical Testing 
Physical testing of Lipitor included visual inspection of the package.  It was found that all 
samples that obtained from different pharmacies look exactly as the original package, and 
the font size printing, the colour of the package, and the logo of the manufacturing 
company are all similar to the original packaging. The tablets were weighed and compared 
to the weight of the originals and found to range between 303 mg to 318 mg for each tablet, 
which is same as original.  It was also noticed that all the tablets colour, size and shape are 
same as that of the originals.   
 
Results of Chemical Analysis : chemical testing of Lipitor was comprised of two analyses. 
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HPLC Analysis:  The analysis of Lipitor is performed by using high performance liquid 
chromatography for the determination of active ingredient in the product (atorvastatin ) 
Thirty three samples of Lipitor were analysed for their assay and related impurities. All 
Lipitor samples were coded with the letter B; the results are shown in table (6.5). 
 
Table (6.5):  Results of Assay and Related Impurities Testing of Lipitor (20mg) 



















B1 0630107 10-2007 9-2010 98.4 0.15 0.37 
B2 0649077 7-2007 6-2010 97.9 0.09 0.44 
B3 0270077 7-2007 6-2010 97.5 0.10 0.47 
B4 007057 5-2007 4-2010 97.4 0.16 0.44 
B5 0649077 7-2007 6-2010 98.9 0.11 0.35 
B6 0630107 10-2007 9-2010 97.8 0.10 0.31 
B7 0270077 7-2007 6-2010 99.2 0.12 0.36 
B8 0630107 10-2007 9-2010 97.3 0.14 0.39 
B9 0630107 10-2007 9-2010 98.5 0.15 0.37 
B10 0630107 10-2007 9-2010 98.1 0.15 0.39 
90%≤ Assay limit ≤110%.  Max. Imp. ≤ 1.5% 

















B11 0630107 10-2007 9-2010 97.3 0.13 0.37 
B12 0270077 7-2007 6-2010 100.4 0.18 0.71 
B13 0630107 10-2007 9-2010 97.9 0.18 0.65 
B14 0049107 10-2007 9-2010 99.0 0.16 0.57 
B15 0649077 7-2007 6-2010 97.0 0.21 0.74 
B16 0649077 7-2007 6-2010 98.7 0.23 0.77 
B17 0630107 10-2007 9-2010 97.5 0.15 0.66 
B18 0630107 10-2007 9-2010 96.3 0.18 0.72 
B19 0330088 3-2008 2-2011 99.1 0.21 0.57 
B20 0330088 3-2008 2-2011 99.1 0.26 0.65 
B21 0649077 7-2007 6-2010 98.9 0.25 0.84 
B22 0049107 10-2007 9-2010 98.9 0.28 0.76 
B23 0630107 10-2007 9-2010 97.6 0.07 0.37 
B25 0649077 7-2007 6-2010 96.9 0.09 0.47 
B26 0330038 3-2008 2-2011 99.0 0.11 0.40 
B27 0330038 3-2008 2-2011 97.2 0.16 0.44 
B28 0270077 7-2007 6-2010 98.5 0.23 0.62 
B29 0630107 10-2007 9-2010 97.1 0.11 0.33 
B30 0330038 3-2008 2-2011 99.3 0.20 0.42 
B31 0630107 10-2007 9-2010 97.3 0.22 0.45 

















B33 0330038 3-2008 2-2011 98.9 0.34 0.51 
 
 
Results, as shown in table (6.5), indicated that the typical content of active pharmaceutical 
ingredients (API) were between 96.3-100.4% while the acceptable limits ranging from 90-
110%. This means that all samples analysed were within the pharmacopoeial limits and are 
considered safe pharmaceuticals. The related impurities in Lipitor are: Atorvastatin amide, 
Desfluoro Atorvastatin, Diastereoisomer, O-methyl Atorvastatin, Atorvastatin lactone and 
Atorvastatin methyl ester (Monar, Damic and Nigovic 2010). The maximum impurity was 
found to be less than 1.5% which is within the acceptable limits. Total impurities were 
found less than 3.5% which indicates that the related impurities analysis as shown in table 
(6.5) was within acceptable limits. Based on the findings it was concluded that there are no 


















Figure (6.6): Chromatograph of Lipitor for Assay 
 
Chromatographic profile of samples of Lipitor indicated that the retention time and the UV-
absorption spectrum shown in figure 6.6 indicated that the sample is Lipitor and no 











Figure (6.7) shows the related impurities of Lipitor, after calculations they were found 
within pharmacopoeial limits. 
 
Results of Dissolution Analysis 
In order to evaluate the formulation effectiveness, dissolution was performed on Lipitor 
since atorvastatin is poorly soluble and special care with formulation and manufacturing 
parameters is a must to insure atorvastatin tablets compliance to the required standards of 
solubility. 
All thirty-three samples were analysed for their drug release and the results are presented in 





Table (6.6): Results of Dissolution Testing of Lipitor (20mg) 
 
 





% Release in 
60 minutes 
B1 0630107 10-2007 9-2010 99.4 
B2 0649077 7-2007 6-2010 101.7 
B3 0270077 7-2007 6-2010 102.1 
B4 007057 5-2007 4-2010 101.6 
B5 0649077 7-2007 6-2010 101.9 
B6 0630107 10-2007 9-2010 101.4 
B7 0270077 7-2007 6-2010 101.2 
B8 0630107 10-2007 9-2010 99.7 
B9 0630107 10-2007 9-2010 100.7 
B10 0630107 10-2007 9-2010 98.9 
B11 0630107 10-2007 9-2010 99.0 
B12 0270077 7-2007 6-2010 98.8 
B13 0630107 10-2007 9-2010 98.8 
B14 0049107 10-2007 9-2010 98.8 
B15 0649077 7-2007 6-2010 100.3 
B16 0649077 7-2007 6-2010 101.0 
B17 0630107 10-2007 9-2010 100.6 
B18 0630107 10-2007 9-2010 101.5 
B19 0330038 3-2008 2-2011 102.3 
B20 0330038 3-2008 2-2011 101.6 
B21 0649077 7-2007 6-2010 101.2 
B22 0049107 10-2007 9-2010 100.8 
B23 0630107 10-2007 9-2010 101.2 
B24 0649077 7-2007 6-2010 101.4 
B25 0649077 7-2007 6-2010 101.8 
% Drug Release Limit ≥ %80 
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% Release in 
60 minutes 
B26 0330038 3-2008 2-2011 101.1 
B27 0330038 3-2008 2-2011 100.7 
B28 0270077 7-2007 6-2010 101.7 
B29 0630107 10-2007 9-2010 101.2 
B30 0330038 3-2008 2-2011 100.7 
B31 0630107 10-2007 9-2010 99.5 
B32 0649077 7-2007 6-2010 98.9 
B33 0330038 3-2008 2-2011 99.2 
 
 
Results of the dissolution analysis for the thirty-three samples as shown in table (6.6) 
showed that the percentage of the drug release for the drug was found between 98.8- 102.3 
while the acceptable percentage limit of drug release, according the United States 
Pharmacopoeia was 80% or over.  These results confirm that these samples were produced 



























Results of Phase Two (Jordan) Survey Test Sample 
Results of the analysis of stage one indicated that no counterfeited drug was found.  
Based on the results of the first phase of the analysis which included only samples from 
Amman, the capital of Jordan, further analysis was needed and more cities were included to 
have a better comprehension of the problem of counterfeit pharmaceuticals. Therefore, it 
has been decided that one of the four drugs will be analysed in the second stage.  For this 
stage, Concor (bisoprolol fumarate) was chosen after discussion with (JFDA) officials who 
have indicated that counterfeited Concor has been found recently in the Jordanian market, 
which was seemingly smuggled from a neighboring country. 
To determine the genuine medicine from the counterfeit one, the physical appearance and 
the chemical results were used as the quality indicators. 
 
7.1 Results of Analysis of Concor 
Concor was subjected to two tests: 
 
7.1.1 Results of Physical Testing 
Physical testing of Concor included visual inspection of the package.  It was found that the 
counterfeit packaging looks exactly as the original package, the font size printing, the 
colour of the package, the logo of the manufacturing company are all similar to the original 
packaging. The tablets were weighed and compared to the weight of the original which was 
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ranged from 171 mg to173.9 mg for each tablet.   It was also noticed that all the tablets 
weights were found within the range, the colour, size and shape of the original. 
 
7.1.2 Results of Chemical Analysis  
The chemical analysis of Concor is performed by using high performance liquid 
chromatography for determination of bisoprolol assay as well as its related impurities. Tests 
included the use of pharmacopoeial method of high performance liquid chromatography 
(HPLC) for all samples.  40 Samples of Concor were analysed to confirm the amount of the 
active ingredients. All Concor samples were coded with the letter A.  Results are shown in 
table (7.1). 
 
Table (7.1):  Results of Assay and Related Impurities Testing of Concor 


















A 34 103219 6-2009 5-2012 101.7 0.17 0.20 
A 35 101759 3-2009 2-2012 100.8 0.03 0.06 
A 36 103219 6-2009 5-2012 101.7 0.03 0.06 
A 37 101759 3-2009 2-2012 101.2 0.14 0.17 
A 38 102529 3-2009 2-2012 98.0 0.13 0.16 
A 39 101759 3-2009 2-2012 100.6 0.13 0.15 
A 40 101759 3-2009 2-2012 100.8 0.13 0.15 
90%≤ Assay limit ≤110%. Max. Impurity ≤0.25% 

















A 41 103219 6-2009 5-2012 100.7 0.11 0.12 
A 42 101759 3-2009 2-2012 98.4 0.05 0.07 
A 43 102530 3-2009 2-2012 98.9 0.05 0.05 
A 44 101759 3-2009 2-2012 99.9 0.05 0.07 
A 45 103219 6-2009 5-2012 101.4 0.03 0.04 
A 46 103219 6-2009 5-2012 100.6 0.04 0.05 
A 47 103219 6-2009 5-2012 98.8 0.09 0.27 
A 48 101759 3-2009 2-2012 99.8 0.09 0.20 
A 49 103219 6-2009 5-2012 100.7 0.09 0.31 
A 50 103219 6-2009 5-2012 100.9 0.09 0.31 
A 51 5787901 8-2008 7-2011 100.6 0.07 0.20 
A 52 101759 3-2009 2-2012 99.8 0.06 0.18 
A 53 102529 3-2009 2-2012 99.7 0.04 0.14 
A 54 102530 3-2009 2-2012 98.6 0.06 0.24 
A 55 103219 6-2009 5-2012 100.9 0.09 0.21 
A 56 103219 6-2009 5-2012 99.5 0.10 0.23 
A 57 102529 3-2009 2-2012 99.9 0.05 0.19 
A 58 103219 6-2009 5-2012 98.8 0.06 0.18 
A 59 103219 6-2009 5-2012 99.3 0.06 0.19 
A 60 101759 3-2009 2-2012 98.7 0.07 0.27 
A 61 104103 7-2009 6-2012 99.0 0.08 0.29 
























A 63 103219 5-2009 5-2012 100.0 0.05 0.16 
A 64 101759 3-2009 5-2012 98.3 0.07 0.27 
A 65 102529 3-2009 2-2012 101.9 0.05 0.14 
A 66 103219 6-2009 5-2012 99.7 0.09 0.29 
A 67 103219 6-2009 5-2012 100.2 0.10 0.30 
A 68 101759 3-2009 2-2012 100.8 0.09 0.27 
A 69 103219 6-2009 5-2012 101.1 0.09 0.27 
A 70 102529 3-2009 2-2012 98.4 0.07 0.29 
A 71 101759 3-2009 2-2012 99.0 0.04 0.11 
A 72 104103 7-2009 6-2012 101.4 0.08 0.26 
A 73 103219 6-2009 5-2012 99.6 0.09 0.28 
 
Seventy three samples of Concor were analysed , thirty three for stage one  and forty for 
stage two as shown in tables (6.2) and (7.1)which indicated that  the typical content of 
active pharmaceutical ingredients (API) was between 96.5-102.7% while the acceptable 
limits ranging from 90-110%. This means that all samples analysed were within the 
pharmacopoeial limits and are considered safe. As for the related impurities, the maximum 
impurity was less than 0.25% which is within the acceptable limit. The total impurities 
were found less than 1.0% which indicates that the related impurities analyses were within 
acceptable limits. Based on these findings it was concluded that there is no counterfeit 































This research objective was to determine the extent to which counterfeit pharmaceutical 
products available in Jordan. To reach this end four life saving pharmaceutical were used 
for HPLC testing.  
In this study, the reason behind selecting these samples of life saving medications was that, 
counterfeiters have frequently targeted these pharmaceuticals in the past due to their high 
prices and high demand which made these products attractive targets to counterfeiters 
according to JFDA officials. Moreover WHO stated that life saving medications globally 
are targeted by counterfeiters due to same reasons (WHO 2006). 
All samples were physically and chemically tested according to the relevant pharmacopoeia 
using high performance liquid chromatography. Dissolution testing was performed for 
Lipitor only in order to evaluate the formulation effectiveness; since atorvastatin is poorly 
soluble and special care with formulation and manufacturing parameters is a must to ensure 
atorvastatin tablets compliance to the required standards of solubility. 
All samples were checked for their active ingredients and their related impurities. 
Impurities are unwanted chemicals that remain with the active could be associated with it or 
created during formulation of the product or could be generated at any synthetic steps or 
upon aging of both active. Therefore, the process of controlling the impurities is considered 
as an important issue in order to ensure the safety, efficacy and have an impact on the 
stability of pharmaceutical products.  That is why pharmacopoeia has an essential role in 
regulating this process by identifying specification limits. 
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Results of  in the study sample. While these results do not necessarily indicate that there are 
no counterfeit pharmaceuticals in the country but it is quite an interesting result to know 
that the country campaign against counterfeit trade seems to be successful in targeting such 
a trade in four very important life-saving pharmaceuticals.  
Obviously, these results did not indicate that there are no counterfeit pharmaceuticals in the 
country as a whole. Counterfeiters tend to move their activity of manufacturing of certain 
types of counterfeit medicines to other products once they realise that the products they 
manufacture are being subjected to further emphasis by authorities. 
As reported earlier, the quality of the four sampled pharmaceuticals used in this study was 
found to comply with the USP quality standard. The explanation for these results is that the 
health authorities’ campaigns against counterfeit drugs have been successful. These results 
confirm the efficiency of the new regulations that JFDA has implemented in 2008, and the 
effective implementation of new strict public health laws which include tougher penalties 
and more effective enforcement measures. 
The establishment and implementation of the “2008 new public health” laws that complies 
with modern international treaties seems to have had an effect of at least significantly 
reducing counterfeit pharmaceutical levels in the country. Jordan initiated a TRIPS 
(Agreement on Trade-Related Aspects of Intellectual Property Rights) implementation 
reform which aimed at placing Jordan in compliance with the world trade organisation 
legislation. The link between counterfeiting and IP is that, trademark law protects against 
the unauthorised use of a product’s name or its appearance in a manner which is similar to 
that used by the legitimate owner. Counterfeiting usually occurs when the counterfeited 
product appears to be made by the authentic manufacturer, even upon close inspection. 
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Therefore intellectual property protection may be used as a tool to help build a useful 
policy to help prevent counterfeiting. Since an unauthorised use of a name or appearance of 
a product in a way which is confusingly similar to that used by the original owner is 
forbidden by intellectual protection laws. Trademark owners can legally sue any party, who 
may produce, sell or distribute counterfeited pharmaceuticals for infringement of their trade 
marks (Falbalrn et al. 2007). 
After results of phase one indicated that there was no evidence of the existence of 
counterfeit pharmaceuticals in,  the researcher decided that further investigation of such a 
conclusion must be conducted in order to provide more validation to these results. 
To reach this end, the researcher started a round of meetings and discussions with JFDA 
officials and professionals with the aim of identifying a pharmaceutical product that might 
have more tendencies to be targeted by counterfeiters due to some special features, such as 
frequency of usage. As a result of this campaign, Concor was identified as the product that 
should be further investigated.  
To do this successfully, the researcher decided to collect samples of Concor from the three 
largest cities in Jordan. 
High Performance Liquid Chromatography (HPLC) tests were performed and results 
confirmed phase one results, no counterfeit products were found.  
These results provided more assurances that governmental measures in Jordan to counter 
this trade were successful. 
Another important factor working for the results of this research is the level of 
sophistication of the technology used in the analysis. This technology is owned and 
operated by a very well-known pharmaceutical manufacturer in Jordan “Jordanian 
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Pharmaceutical Manufacturing Co. PLC” which operates state of the art pharmaceutical 
manufacturing facilities which were made accessible for the researcher to use with no 
limitations what so ever. 
Another contributing factor to the success of this research was the use of HPLC as a 
quantitative testing method which has proven to be reliable and able to accurately quantify 
the active ingredients present in the pharmaceutical preparations, as discussed earlier in this 
research.  
The major advantage of HPLC is that it is a sensitive, accurate and precise method of 
analysis. It allows a complex analysis to be done in reasonable period of time and can 
accomplish the separation of components in a more complete manner (Ho and Lin 1996). 
HPLC is considered widely as a stability indicating method which selectively separates 
each active ingredient from its degradation products and in addition separates it from its 
process impurities and formulation excipients (Ho and Lin 1996)     
Therefore this testing method has a qualitative as well as quantitative nature. It also has the 
ability to detect the related impurities in the product 
 Despite these advantages, there are some limitations of this method. This method can 
detect the inadequacy or absence of active ingredient but cannot detect correct active 
ingredients present in correct dosage form but manufactured by illicit laboratory or 
manufacturer (Fraud counterfeits). 
Therefore, results of testing using HPLC seemed adequate to increase the level of 
confidence in the results. 
The researcher has validated the ability of HPLC to discriminate between counterfeited and 
non- counterfeit products by applying HPLC testing to samples of known counterfeit 
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products obtained by authorities as described earlier in the results in known counterfeit 
chapter. These results confirmed that samples were actually counterfeited. 
This testing has provided the researcher with more confidence in the ability of HPLC as an 
analysis method.  
However, in order to increase the level of confidence in the results of the analysis, the 
researcher has decided to apply more tests. Therefore, Infrared spectrometer (IR 
Spectrometer) was used for   the identification of the existence of active ingredients in the 
samples. All batches of the sampled pharmaceuticals were subjected to the analysis of 
Infrared Spectroscopy (IR Spectroscopy).  
IR spectroscopy involved collecting absorption information and analysing it in the form of 
an IR spectrum, followed by a comparison with a reference spectrum. Results of this testing 
showed that all of the study samples contained the required active ingredients, which 
confirms the results obtained using HPLC method. 
In an attempt to identify the composition of the counterfeit samples, further analysis of the 
ingredients was performed such as identification of starch, lactose and hydroxypro-
pylcellulose. 
The above analysis revealed that, a counterfeit drug has characteristics different from the 
genuine one. Some counterfeited drug has no active ingredients at all, while some others 
have some active ingredients significantly below the USP specified limits. 
These results indicated that the (HPLC) analysis could successfully differentiate counterfeit 































9. Conclusion and Recommendations 
The main objective of this study was to determine whether there are counterfeit 
pharmaceuticals exist in the Jordanian market or not.  To reach this end the study has 
examined 172 samples, which were collected during the period from March 2009 to 
February 2010 from the three most populated cities in the country namely, Amman (capital 
of Jordan), Zarqa and Irbid. 
The study examined  33 samples of co-Diovan (valsartan, hydrochlorothiazide) used for 
treatment of high blood pressure, 33 samples of Lipitor (atorvastatin-calcium) used for 
cholesterol lowering, 33 samples of Plavix (clopidogrel) used for preventing blood clots in 
arteries, and 73 samples of Concor (bisoprolol fumarate) used for reducing high blood 
pressure in patients. 
All samples were physically and chemically tested according to compendial requirements 
using high performance liquid chromatography and dissolution testing was performed for 
Lipitor only. 
Results of all tests done in this study have not been able to detect any presence of 
counterfeit pharmaceuticals in the study sample. While these results do not necessarily 
indicate that there are no counterfeit pharmaceuticals in the country but it is quite an 
interesting result to know that the country campaign against counterfeit trade seems to be 
successful in targeting such a trade in four very important life-saving pharmaceuticals.  
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This conclusion is conservatively stated here due to the fact that the study survey was 
limited to the samples subjected to analysis which in fact indicate that such a conclusion 
cannot be generalised to reflect the nature of the problem of counterfeit pharmaceutical in 
Jordan. 
Obviously, these results did not indicate that there are no counterfeit pharmaceuticals in the 
country as a whole. Counterfeiters tend to move their activity of manufacturing of certain 
types of counterfeit medicines to other products once they realise that the products they 
manufacture are being subjected to further emphasis by authorities. 
As reported earlier, the quality of the four sampled pharmaceuticals used in this study was 
found to comply with the USP quality standard. The one feasible explanation for these 
results is that the health authorities’ campaigns against counterfeit drugs have been 
successful.  These results confirm the efficiency of the new regulations that JFDA has 
implemented in 2008, and the effective implementation of new strict public health laws, 
which include tougher penalties and more effective enforcement measures. 
The main conclusion, however that can be derived from the results of this study is that, no 
indication of the presence of counterfeit pharmaceuticals in the sampled products used in 
the study in the Jordanian market given the limitations of the resources and budget made 
available for the conduct of this study. This study used an organised design to detect if 
counterfeit elements are present in the study samples. A validity test was employed in order 
to assure that the study is really designed in a way that permits reaching reliable results. 
This test used known counterfeit samples which, when subjected to exactly the same testing 




This study is considered as the first comprehensive research to evaluate the presence of 
counterfeit pharmaceutical products in Jordan. One of the major problems faced by the 
researcher was the absence of serious previous literature on this topic in Jordan and the 
Middle East. 
Since 2008, Jordan has been engaging in an anti-counterfeit campaign in terms of increased 
legal measures, tough penalties, and increased inspection. Drug regulations have also been 
upgraded and several strategies were implemented as means to combat counterfeit drugs. 
Global awareness in the battle against counterfeit pharmaceuticals is also increasing, the 
World Health Organisation (WHO) fact sheet (WHO 2003) on counterfeit medicines refer 
to them as ‘an enormous public health challenge’. 
Predictions are that pharmaceutical counterfeiting will undergo a more than 90% increase 
in their sales by the year 2010 (WHO 2006). 
Despite this global trend, Jordan has recognised the size of the problem and has made some 
degree of progress in dealing with it through applying stronger regulations. However there 
remains much work to be done to maintain the safe and secure supply of quality of 
pharmaceuticals in Jordan. 
Prior to the year 2008, it was noticed that during the period from 2005 to early 2008 there 
was a noticeable presence of counterfeit pharmaceuticals in the Jordanian market but since 
the implementation of the new regulations this problem is significantly reduced. 
This study suggests that due to the implementation of new strict regulatory measures with 
harder penalties than before, the quality of pharmaceuticals has improved to the point that it 
was hard to find counterfeit pharmaceuticals in the market compared to the past.  
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The Jordanian Food and Drug Administration (JFDA) have conducted workshops for the 
Judiciary.  Judges and law officers from twelve district of Jordan have participated in the 
workshops. Workshops included the following dimensions: 
1. The definition of counterfeit pharmaceuticals and what really constitutes counterfeit 
pharmaceuticals and how they affect public health. 
2. The differentiating factor between smuggled and counterfeit pharmaceutical. It is worth 
mentioning here that the public perception is that, it is acceptable to use smuggled 
products because they think it is as good as any other original products. 
Workshops have emphasised the fact that, smuggled drugs actually are different from other 
smuggled goods such as clothes for example. Smuggled drugs sometimes contain no active 
ingredients, or contain the wrong ingredients, less than the therapeutic levels of the active 
ingredients and finally they might contain toxic ingredients, therefore they constitute a 
health hazard.  
3. Participants were informed that Jordan has been struggling for years to protect brand 
names through its judiciary system, and recently they enacted more than 30 laws to 
combat piracy and establish an ongoing training program for judges and judiciary 
employees to comply with national and international legislation against piracy and 
counterfeit (Al- Iryani and   Ba-swaid 2009). 
4. One of the main objectives of this workshop was to Judges who are involved in the 
prosecution of counterfeiters, information about counterfeit pharmaceuticals, and the 
importance of implementing severe penalties for individuals or firms who might engage 
with this trade. 
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One important conclusion as a result of this workshop, a decision was taken that only well 




The researcher recommends the following in order to re-enforce governmental 
accomplishments in the area of controlling the quality of pharmaceuticals in the country: 
1. In Jordan, life-saving pharmaceuticals as well as antibiotics, and almost all 
medications can usually be bought over the counter without prescription. Prescription 
is required only for sedatives, tranquilisers and narcotics. Pharmaceuticals used in this 
study are usually available over the counter without prescription. Therefore the 
researcher would recommend that dispensing of pharmaceuticals upon prescription 
should be strictly regulated which would be expected the possibility of selling 
counterfeit pharmaceuticals. 
2. It is also recommended that an extra emphasis should be given to the process of 
vigorous testing of the quality of imported pharmaceuticals and the routine testing of 
new supplies in order to insure compliance with GMP. 
3. As part of the health authorities’ campaign against illegal dealing with pharmaceutical 
products, the level of awareness of physicians and pharmacists should be enhanced. 
When they are confronted with ineffectiveness of a commonly effective therapy, they 
should wonder about the quality and origin of the medicine. All parties concerned must 
know that counterfeit drugs are dangerous and sometimes life threatening. 
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4. Continuing education of consumers and health professionals about the dangers of 
counterfeit pharmaceuticals should be considered as a way of life.  They should be 
encouraged to report any changes regarding the color, shape, size and any other 
differences in pharmaceuticals’ attributes and characteristics. It has been noticed that in 
many cases, patients regularly discover that the pharmaceuticals that they are using are 
not the same as they have been familiar with, and report that to their physicians. 
5.   The quality of all pharmaceuticals circulating in the distribution chain should 
continuously be monitored by sampling and analysing them on a regular basis to 
ensure that the quality and safety of pharmaceuticals are assured. 
6. It is also important to address the issue of cooperation among various government 
organisations, health workers, industry, and wholesalers.  An integrative network of 
cooperation among these parties is assumed to be critical to maintain the integrity and 
security of Jordan pharmaceuticals. 
7. It was reported that most confiscated pharmaceuticals came from neighboring 
countries. Therefore, sharing of information and cooperation with neighboring 
countries should be encouraged in order to stop the smuggling of counterfeit 
pharmaceuticals. 
8.  The regulatory authorities should ensure that pharmacists, hospitals, and clinics must 
obtain their pharmaceuticals from known sources such as a major wholesaler. 
9. In Jordan, internet purchases are not a wide spread practice yet. Actually buying 
pharmaceuticals from the internet is very limited unlike other goods. But such a 
practice might suddenly be realised. Therefore, authorities must take a proactive 
approach in dealing with such an issue in the future.  
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10.  Finally, it is recommended that regulatory authorities should develop an information 

















































- Abdo-Rabbo, A. Bassili, A. Atta, H. (2005) ‘The Quality of anti-malarials available in 
Yemen.’ Malaria Journal [online]4, (28) available from 
<http://www.malariajournal.com/content/4/1/2> [24 February 2009] 
 
- Aka, E. Legris C, Tsuyoshi T, Matsushita R and Kimura K.(2005) ‘Counterfeit medicine 
detection by authenticity investigation a Pilot study in the street market of  
Cote d' Ivoire.’Japanese Journal of Social Pharmacy  24,(2) 7-16.Available from  
<http://www.sciencelinks.jp/j-east/.../000020061606A0614750.php.>[2 February 2009]  
 
- Alabdalla, M. (2005)’ Chemical Characterization of Counterfeit Captagon Tablets 
seized in Jordan.’ Forensic science International [online] 152, 185-188. Available 
from<http://www.sciencedirect.com> [28 Feb 2009]   
 
- Alfadl, A.A. Abdoon S, Elamin M, and Gar Elnabi N. (2006)’Quality of Anti-malarials 
Drugs in Sudan: Results of Post-Marketing Surveillance.’ Sudanese Journal of Public 
Health1, (2).  
 
- Al-Hussaini, SR. (1996)’ Counterfeit Captagon: an Analytical Study.’ Science& Justice 
36, (3) 139-142. [Online] Available from 
< http://www.scienceandjusticejournal.com/article/S1355-0306  (96)72588-1.> 
 [30-January 2010] 
159 
 
- Al-Iryani A. and Ba-swaid, H. (2009)' some 30-40% of Medicines Sold locally is 
counterfeit’ Saudi Gazette [online] available from 
<http://www.saudigazette.com.sa/index.cfm?method=home.> [9-May -2009] 
 
- Amin, A.A.  and Kokwaro, G.O. (2007) ’Anti-malarials Drug Quality in Africa.’ Journal 
of Clinical Pharmacy and Therapeutics 32, (5) 429-440. [Online] Available from 
<http://www.ingentaconnect.com/content/bsc/jcpt/2007/00000032/00000005/art00002?> 
Crawler=true [9-May 2009]   
 
- Andrew, J. (2007) ‘Bitter Pills.’ Pub Med Central Journal [online] 335, (7630) 1120-








- Arfwedson J. (2004) ‘Parallel Trade in Pharmaceuticals’ A Policy Report 182. Texas-




- Bader R. (2004) Medicine Prices, Availability and Affordability in Jordan. Report of a 
survey conducted in 2004 in Amman, Irbid, Zarqa and Karak using the WHO/HAI Price 
measurement methodology [online] <http://www.emro.who.int/dsaf/dsa786.pdf > 
[1June 2010] 
- Bate, R, Coticelli PH, Tren R and Attaran A.  (2008)’Anti-malarials Drug Quality in the 
Most Severely Malarious Parts of Africa- a Six Country Study.’ PLoS One [Online] 3 (5) 
Available 
from<http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0002132> 
[10 April 2009]  
- Beermann B, Groschinsky-Grind M, Rosén A. (1976). "Absorption, metabolism, and 
excretion of hydrochlorothiazide". Clin Pharmacol Ther 19 (5 (Pt 1)): 531–7. 
 
- Berger PB. (2007) ‘The Theinopyridines in Coronary Artery Diseases’ Current 
Cardiology Reports 1, (3) 192-198. 
 
- Bogdanich W. (2007)’ Free Trade Zones Ease Passage of Counterfeit Drugs to U.S.’ The 
New York Times 17 December. 
 
- Briggs GG, Nageotte MP (2001). "Fatal fetal outcome with the combined use of 
valsartan and atenolol". The Annals of Pharmacotherapy35 (7-8): 859–61. 




- Catizone C. A. (2006) ’Counterfeit Drugs and States’ Effort to Combat the Problem.’ 
Journal of Pharmacy Practice 19, (3) 165-170.   
 
- Caudron J.M., Ford N., Henkens M., Mac C., Kiddle-Monroe R., and Pinel J. (2008) 
‘substandard medicines in resource-poor settings: a problem that can no longer be 
ignored.’ Tropical Medicine and International Health 13, (8) 1062-1072.  
 
- Clarck, E. (2008)’Counterfeit Medicines: The pills that Kill.’ Telegraph co.uk 5 April  
 
- Celia, F. (2005) ‘States Move to Comply with Drug Pedigree Laws’ Drug Topics 6 June 
 
- Cockburn R., Newton PN. ,Agyarko EK., Akunyili D., and White NJ. (2005) ‘The 
Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate 
The Dangers.’ PLoS Medicine Journal [online] 2(4) Available from 
<http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1062889&blobtype=pdf>[10 
may 2009]   
 
- Cockburn R. (2005) ’Death by Dilution’ the American Prospect [Online] available 
from<http://www.prospect.org/cs/articles?articleId=10650> [29 April 2009]   
 
- Crooker K. (2009) ‘RFID Technology as Sustaining or Disruptive Innovation:    
Applications in the Healthcare Industry.’ European Journal of Scientific Research 37,    
(01)160-178.   
162 
 




- Deisingh AK. (2005) ‘Pharmaceutical Counterfeiting’ the Analyst 130, 271-279.  
 
- Deus L. (2006) ‘Technological Roles in Combating Drug Diversion and Counterfeiting’ 
Journal of Pharmacy Practice 19, 146.   
 
- Falrbalrn D, Shum A, Schonlg W, and Milbradt C (2007)’ Intellectual property and the 
fight against Counterfeit drugs’ from Innovation to Commercialization 2007.A 
supplement to Intellectual Asset Management Magazine,www.iam-magazin.com. 
 
- Gaudiano, MC. Maggio AD, Cocchieri E, Bertocchi P, Alimonti S and Valvo L  
(2007).’Medicines informal market in Congo, Burundi and Angola: Counterfeit and 
substandard anti-malarials.’ Malaria Journal [online] 6(22) available from 
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1810297> [28 January 2010]   
 
- German Pharma Health Fund (GPHF) (2004)’ Counterfeit Medicines- An unscrupulous 
Business’ [on line] Germany: Merck, Darmstadt. available from 
<http://www.gphf.org/web/en/minilab/hintergrund_arzneimittelfaelschungen.htm> 
[August 7 2009] 
163 
 
- Ghosn, Z. (2008) ‘Lebanon Launches Campaign to Counter Fake Drugs.’ Science and 
Development Network   [online] available from 
<http://www.scidev.net/en/health/standards-of-care/lebanon-launches-campaign-to- 
Counterfakedrugs.html?utm_source=link&utm_medium=rss&utm_campaign=en_health
_standardsofcare launches campaign to counter fake drugs. > [July 13 2009]   
 
- Global Intellectual Property News Agency Ag-Ip news (2009)’JFDA Seizes Counterfeit 
Medicines, Shuts Down 180 Pharmacies in Jordan’ 3 February  
 
- Green, M., Mount, D. and Wirtz, R. (2001) ’Authentication of artemether, artesunate and 
dihydroartemisinin anti-malarials tablets using simple calorimetric method’ Tropical 
Medicine and International Health6, (12) 980-982. 
 
- Hall, R. (2009) ‘Drug Companies Attack Fake Medicine’ Daily Star 17 December. 
 
- Halteh S. (2008)’Unified Efforts Needed to Combat Counterfeit Medicines in Jordan.’ 
Ag-Ip News[Online] available from 
<www.ag-inews.com/GetArticle.asp?Art_ID=5736&lang=en> [15 April 2009] 
 
- Ho CH. And Lin G. (1996)’Stability-Indicating High Performance Liquid 
Chromatographic Assay Method for Drugs in Pharmaceutical Dosage Forms: Part 1’ 




- Humphreys A. (2010) ‘200: World’s Best Selling Medicines-Sales’ Med Ad News Guide 
to Pharmaceutical Marketing and Interactive Services. 
 
- IFPMA ( International Federation of Pharmaceutical Manufacturers   & Associations 
(2006)' Conference on’ Corporation in Combating Health Threat Posed by Counterfeit 
Medicines.' Rome News Release (2006) Guy W. (ed.) Geneva, Switzerland. 
 
- IMS (International Market Statistics (2010) A Report on Sales Screening in Jordan. 
Amman : Jordan 
 
- Ivanovic D., Malenovic A., and Jancic B. (2007) ‘Monitoring of Impurity Level of 
Valsartan and Hydrochlothiazide Employing an RP-HPLC Gradient Mode.’ Journal of 
Liquid Chromatography & Related Technologies 30, 2879-2890. 
 
- JFDA Jordan Food and Drug Administration (2008). The Hashemite kingdom of Jordan. 
Public Health Law No 47. 
 
- Jordan NHRHO (2009) National Human Resources for Health Observatory available 
from:[on line]<http//www.jordannap.net/hhc/nhrho/index.asp?it=2&m=2>[5-Dec.2009] 
 
- Kelesidis Th., KelesidisI., Rafailidis PI., and Falagas ME. (2007) ‘counterfeit or 
substandard antimicrobial Drugs: a review of the scientific evidence.’ Journal of 
Antimicrobial Chemotherapy [online] 
165 
 
available from <http://Jac.oxfordjournals.org/cgi/reprint/dkm109vl> [23july 2009]   
 
- Khan, A. and Ghilzai, K. (2007)’ Counterfeit and Substandard Quality of Drug: The need 
for an effective and stringent regulatory control in India and other developing countries.’ 
Indian Journal of Pharmacology39, (4) 206-207.    
 
- Kontnik LT. (2006 a)’Manufacturer and Industry Responses to Counterfeiting’ Journal 
of  Pharmacy Practice19, (3) 141. 
 
- Kontnik LT. (2006 b)’Manufacturer and Industry Responses to Counterfeiting’ Journal 
of Pharmacy Practice19, (3) 145. 
 
- Kyriacos, S. Mroueh M, Chahine P. and Khouzam O. (2008).’Quality of amoxicillin 
formulations in some Arab countries.’ Journal of Clinical Pharmacy and 
Therapeutics33,(4) 375-379 [Online] available from 
<http://www3.interscience.wiley.com/journal/120749538/abstract > [5 May2009] 
 
- Lancaster I. (2008)’Holograms and Anti- counterfeiting Sophisticated replication 
techniques have made counterfeiting and fraud a serious threat to the pharmaceutical 




- Lon, C.T., Tsuyuoka R, Phanouvong S, Nivanna N, Socheat D, Christophel E.M. and 
Smine A.  (2006). ’Counterfeit and Substandard anti-malarials Drugs in Cambodia.’ 
Transaction of the Royal Society of Tropical Medicine and Hygiene 100, (11) 1019-1024. 
 
- Lybecker, K.  (2007)’ RX Roulette: Combating Counterfeit Pharmaceuticals in 
Developing Nations.’ Managerial and Decision Economics Journal [Online] 28, (4-
5)509-520. Available from< http://www.interscience.wiley.com>[12 May 2009] 
 
-Marks JW (2007).”Valsartan” MedicineNet.Com available [online 
from<http://www.medicinenet.com/valsartan/article.htm.[ 2010-03-04] 
 
- Martijn T.H. (2003)’Health Risks of Counterfeit Pharmaceuticals.’ Drug Safety [online] 
26, (14) 991-997 available from< 
http://adisonline.com/drugsafety/Abstract/2003/26140/Health_Risks_of_Counterfeit_Pha
rmaceuticals.1.aspx> [December 10-2009] 
 
- Mason, P. and Ali, A. (2005) ‘Pharmaceutical Chaos’ The Pharmaceutical Journal 
[online] 274 (7334) 115-116 available from< 
http://www.pharmj.com/pdf/articles/pj_20050129_iraq.pdf>[May 15, 2009] 
 
- Medicine Net.Com (2010) Medications and Drugs [online] available 




- (MHRA) 2006 ’Guidance for Pharmacists: how to detect and report Counterfeit 
Medicines.’ Pharmaceutical Journal [online] 276, 627-628.Avialable from 
<http://www.pharma.com/pdf/articles/pj_20060527_guidance.pdf> [June 6 2009]  
 
- Mohan A, Hariharan M, Vikraman E, SubbaiahG,Venkataraman BR, and Saravanan 
D.(2008) ‘Identification and Characterization of a principal Oxidation impurity in 
clopidogrel drug substance and drug product.’ Journal of Pharmaceutical & Biomedical 
Analysis 47(1), 183-189. 
 
- Morei R. (2009) ‘Counterfeit Medicines’ addounia [online] available from: 
<www.addounia.tv/article.jsp?smcache=true&id=247> [Dec.12-2009] 
 
- Mornar A., Damic M. and Nigovic B. (2010) ‘Separation, Characterization and 
Quantification of Atorvastatin and Related Impurities by Liquid Chromatography- 
Electro spray Ionization Mass Spectrometry.’ Analytical Letters 43, (18) 2859-2871. 
 
- Morris, J. and Stevens, Ph. (2006)’ Counterfeit medicines in Less Developed Countries:    
Problems and Solutions.’ International Policy Network London, UK.   
 
- Newton P. Green MD, Fernandez F, Day NPJ, and White NJ.  (2006a) ‘Counterfeit anti-
infective Drugs.’ Lancet Infectious Diseases [Online] 6, (9)602-613.Available 
from<http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(06)70581-




- Newton, PN, McGready R, Fernandez F, Green MD, Sunjio M, et al. (2006 b) 
‘Manslaughter by Fake Artesunate in Asia- Will Africa Be Next?’.PLoS Medicine 
Journal [online] 3, (6) Available from: 
<http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.003032
4;jsessionid=EDA02AC766EB0473ACBBDB4700F3EEC4> [25 February 2009]  
 
- Newton, P. Fernandez FM., Plancon A., Mildenhall DC., Green MD., Ziyong L., 
Christophel EM., Phanouvong S., Howells S., McIntosh E., Laurin P., Blum N., 
Hampton Ch., Faure K., Nyadong L., Soong C.W., Santoso B., Zhiguang W., Newton J. 
and Palmer K.,(2008) ‘ A collaborative Epidemiological Investigation   Into the Criminal 
Fake Aretesunate Trade in South East Asia.' PLoS Medicine Journal [online] 5, (2) 
Available from 
<http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0050032>[24 
February 2009]   
 
- Obaid, A. (2009).’Quality of Ceftriaxone in Pakistan: Reality and Resonance.’ Pakistan 
Journal of Pharmaceutical Sciences 22, (2) 220-229.   
 
- Onwujekwe O. Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V and 
Okonkwo P. (2009).’Quality of Anti-malarials drugs provided by Public and Private 
health care providers in South-East Nigeria.’ Malaria Journal [on line] 8, (22) available 




- Pereillo J, Maftouh M, Andrieu A, Uzabiaga M, Fedeli O, Savi P, Pascal M, Herber J. 
Maffrand J and Picard C.(2002) “Structure and Stereochemistry of the active Metabolite 
of Clopidogrel” Drug Metabolism and Disposition[online] 30, (11): 1288–1295 
Available from http://dmd.aspetjournals.org/content/30/11/1288.full.pdf [ 22 September 
2011] 
 
- Public Health and Pharmacy Law (2008), Amman:  Law No.47 Section 7. 
 
- Royal Decree (2001) the Hashemite Kingdom of Jordan. Drug & Pharmacy Law. 
Amman: Provisional law No.80 
 
- Rudolf, PM. Bernstein, IB. (2004) ‘Counterfeit Drugs.’ The New England Journal of 
Medicine.   [Online] 350, (14)1384-1386.Avialable from 
<http://content.nejm.org/cgi/reprint/350/14/1384.pdf?ijkey=bad27726da332c6a35be35ca
bd1a58b9b5018c54> [9 may2009] 
 
- Sabag R. (2008) ‘Lack of legislations, lack of coordination is the factors behind the 
selling of counterfeit pharmaceuticals.’ Al-Arab alyoum8 February: 8  
 
- Simon T; Verstuyft, C; Mary-Krause, M; Quteineh, L; Drouet, E; Méneveau, N; Steg, 
PG; Ferrières, J et al. (January 2009). “Genetic Determinants of Response to Clopidogrel 
and Cardiovascular Events". The New England Journal of Medicine360 (4): 363–75. 




-Stevens Ph. (2006) ‘Counterfeit Drugs: getting to the root of the Problem' Medical 
Progress Today 24 March. 
- Tipke, M., Diallo, S., Coulibaly, B., Storzinge, D., Hoppe-Ticky, T., Sie, A., and Muller, 
O. (2008)’ Substandard Anti-malarial Drugs in Burkina Faso.’ Malaria Journal [on   line] 
7, (95) available from <http://www.malariajournal.com/content/7/1/95> [25-march2009]   
 
- U.S. Pharmacopoeia (2004) A Review of Drug Quality in Asia with Focus on Anti-
Infectives. ‘BS’ the Standard for Quality. United States 
 
- U.S. Pharmacopoeia (2006) Material Safety Data convention. 
 
- U.S. Pharmacopoeia (2010) what is Pharmacopoeial Forum? United States 
 
- USP Monographs ( 2007)Pharmacopoeia Forum volume 29(3) pp.609 [online] available 
from<http://www.pharmacopeia.cn/v29240/usp29nf24s0_m9792.html> 
 
- US Pharmacopoeia (2011) USP‘s Pending Monographs Guideline. Available from< 
http://www.usp.org/pdf/EN/pendingStandards/m5601.pdf> 
 
- Walt, B. (2007) ‘Free Trade Zones Ease Passage of Counterfeit Drugs to U.S.’ The New 




- Wertheimer, A. and Norris, J. (2009)’ Safeguarding against Substandard/ Counterfeit 
drugs: Mitigating a macroeconomic pandemic.’ Science Direct research in Social and 
Administrative Pharmacy [Online] 5, (1) 4-16. Available from 
<http://www.sciencedirect.com/science?_ob=ArticleListURL&_method=list&_ArticleLi
stID=930585366&_sort=d&view=c&_acct=C000050221&_version=1&_urlVersio-
n=0&_userid=10&md5=24d3f1e0e6c426e30cf6e8eafc59a140>[10 June2009]  
 
- Williams RL. (2006) ’US Pharmacopoeia Council of Experts 2005-2010: Work Plans, 
New Revision Approaches, and Other Enhancements.’ AAPS Journal. 2006; 8(4): 661-
664. 
 
- World Health Organisation (1999) A Report on Counterfeit Drugs: Guidelines for the 
development of measures to combat counterfeit drugs WHO/EDM/QSM/99.1.Geneva: 
Switzerland.  
 
----- (2003a), Counterfeit Drugs  Fact Sheet, Nov.2003. Geneva: Switzerland. 
 
----- (2003b) The Quality of Anti-malarials- A Study in Selected African Countries’ 
Essential Drug and Medicines Policy Series N 030. Geneva: Switzerland.  
----- (2005)  Counterfeit Medicines Geneva: Switzerland.  
 




----- (2006 b) Quality assurance of pharmaceuticals; a compendium of guideline and  
Related materials. Vol 2, Geneva: Switzerland.  
----- (2007 a) General Information on Counterfeit Medicines Geneva: Switzerland. 
----- (2007 b)’Essential Medicines List (EML)’ Fact sheet N 325. Geneva:    Switzerland 
----- (2008) ‘Drug Information’ vol22,  No.2. Geneva: Switzerland. 
----- (2009)  Regional office for the Eastern Mediterranean, Country Profiles Geneva: 
Switzerland.  
------ (2010)‘ Epilepsy in the WHO Eastern Mediterranean Region’ Regional Office for 
the Eastern Mediterranean, Cairo. 
 
- Young, D. (2004).’Counterfeit drugs lawsuit point’s finger at wholesaler, pharmacy.’ 
American Society of Health System Pharmacists [Online] 61, 1980-1987.  Available from 
<http://www.ashp.org/import/news/HealthSystemPharmacyNews/newsarticle.aspx?id=1
667> [10 February 2010] 
 
- Zyiadat, A. (2009) ‘closing down 33 pharmacies for the last five months of this year.’ Al 




























































Background about Jordan 
 
Jordan is situated in the Middle East, bordered to the north and north-east by Syria and Iraq,  
to the south by Saudi Arabia and Gulf  of Aqaba, and to the west by the occupied west 
bank. 
Jordan Map 
The total population was 5.85 million in 2008, with a 2.3% annual growth rate.  
The majority of the population (83 %) lives in urban areas, and life expectancy at birth was 
73 years in 2008, with 3.2% of the population over the age of 65 years (WHO 2009).  
This item has been removed due to third party copyright. The unabridged version of the thesis can be 
viewed at the Lanchester Library, Coventry University. 
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Jordan is classified as a lower-middle income country with a GDP per capita of US$ 2672 
(WHO 2009).The total expenditure on health services in 2008 accounted for 9.6% of the 
GDP (WHO 2009).                             
In 2003, the expenditure on pharmaceuticals in Jordan was JD 211 million (about US$ 295 
million. Over the last 5 years, the average growth rate has been about 3%.  This is due to 
increasing medicine costs and consumption rates (Bader 2004).  
The health system in Jordan consists of public, private and nonprofit organisations. 
 But the main provider of health services is the public sector which consists of: 
 Ministry of Health (MOH), the main provider of health care, which provides coverage 
for public employees and their dependants, other individuals, certified as poor, and 
disabled.  
 The Royal Medical Services (RMS), which provide coverage for military personnel and 
their dependants, and other referrals from MOH.  
 Other smaller public programs include several universities-based programs, such as 
Jordan University Hospital (JUH) in Amman and King Abdullah Hospital (KAH) in 
Irbid, which provide coverage for university employees and their dependants. 
The public health sector is composed of tertiary hospitals, primary health care centers, and 
rural health posts (Bader 2004). 
The private sector provides coverage for companies, employees either through self-insuring 
or through the purchase of private health insurance. 
Local nonprofit Organisations:  charitable organisations such as the non-government 
organisations (NGOs), Zakat Fund (Islamic alms giving), and other charitable societies. 
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International agencies:  which offer free medical services include United Nations Relief and 
Works Agency (UNRWA), charitable societies under the umbrella of the General Union of 
Voluntary Societies (GUVS), and the foreign community centers administered with 
assistance from international groups such as Caritas and Radda Barnen (Swedish Save the 
Children) (Jordan NHRHO 2009).  
Usually 68% of Jordan’s population is formally covered through various health insurance 
programs: public sector 48% private sector and UNRWA 20% programs, while 32% has no 
formal coverage. Yet, these individuals can purchase services at MOH facilities at highly 
subsidised prices (WHO 2009).              
The Jordanian pharmaceutical market consists of imported pharmaceuticals, which 
represents 75% and local manufactured pharmaceuticals, which represent 25%. Most of the 
locally manufactured pharmaceuticals are generic, which are usually sold under 
commercial name (branded generics). 
About 5% of the local pharmaceutical products are manufactured under license through an 
agreement with the originator brand manufacturer and there is some local labeling and 
packaging undertaken using products supplied in bulk from the originator company.  
Public sector pharmacies are attached to health centers or public hospitals.  The private 
sector is composed of independent community pharmacies and chain pharmacies as well as 
hospital pharmacies located in private health facilities. 
The sale of medicines is regulated by Pharmacy and drug Law as enforced by Jordan Food 
and Drug Administration (JFDA). Prices of medicines are regulated and registration of a 
product does include setting of prices which is normally lower for locally manufactured 



























Definition of counterfeit drugs in many Countries 
 
In Nigeria for example, counterfeit was defined (WHO 2007a) as:  
Any drug product which is not what it purports to be; or any drug or drug product which is 
so colored, coated, powdered or polished that the damage is concealed or which is made to 
appear to be better or of greater therapeutic value than it really is, which is not labeled in 
the prescribed manner or which label or container or anything accompanying the drug bears 
any statement, design, or device which makes а false claim for the drug or which is false or 
misleading; or any drug or drug product whose container is so made, formed or filled as to 
be misleading; or any drug product whose label does not bear adequate directions for use 
and such adequate warning against use in those pathological conditions or by children 
where its use may be dangerous to health or against unsafe dosage or methods or duration 
of use; or any drug product which is not registered by the Agency in accordance with the 
provisions of the Food, Drugs and Related Products” (Registration, etc.) Decree 1993,  as 
amended. 
In Pakistan counterfeit drug was defined as: 
“..а drug, the label or outer packing of which is an imitation of, resembles or so resembles 
as to be calculated to deceive, the label or outer packing of а drug manufacturer.” 
In the Philippines, the Republic Act No. 82036 defined counterfeit drug/medicine to mean: 
..."Medical products with correct ingredients but not in the amounts as provided there 
under, wrong ingredients, without active ingredients, with insufficient quantity of active 




 It is а drug which is deliberately and fraudulently mislabeled with respect to identity and/or 
source or with fake packaging, and can apply to both branded and generic products.  
It shall also refer to the drug itself, or the container or labeling thereof or any part of such 
drug, container or labeling bearing without authorisation the trademark, trade name or other 
identification mark or imprint or any likeness to that which is owned or registered in the 
Bureau of Patent, Trademark, and Technology Transfer in the name of another natural or 
juridical person а drug product refilled in containers by unauthorised persons if the 
legitimate labels or marks are used.  An unregistered imported drug product, except drugs 
brought in the country for personal use as confirmed and justified by accompanying 
medical records, and а drug which contains no amount of or а different active ingredient, or 
less than 80% of the active ingredient it purports to possess, as distinguished from an 
adulterated drug including reduction or loss of efficacy due to expiration.” 
The United States Federal Food, Drug and Cosmetic Act' defines а counterfeit drug as,  
"...а drug which, or the containers or labeling of which, without authorisation, bears the 
trademark, trade name, or other identifying mark, imprint, or device or any likeness thereof, 
of а drug manufacturer, processor, packer, or distributor other than the person or persons 
who in fact manufactured, processed, packed, or distributed such drug and which thereby 
falsely purports or is represented to be the product of, or to have been packed or distributed 
























New regulation versus the old regulation 
 
The “Pharmacy practice law” was established in 1972 and implemented since then. The 
pharmacy profession faced many challenges; the most important one was the trade and 
manufacturing of counterfeit pharmaceuticals. The law did not have any specific 
description for counterfeit pharmaceuticals due to the fact that, these products were not 
known at that time therefore no punishments were mentioned. When any unlawful 
counterfeit like act was encountered, judges were empowered by law to deal with it on a 
case by case basis as a smuggling issue.  
In the year 2001 a provisional law called “drug and pharmacy law” was enacted. The law 
has the following relevant articles: 
 
Article 90 
 “In case of any violation by the Pharmacist in charge of the provisions of this law, the 
Minister or his deputy may, under the inspector’s report, take the following actions:- 
 Giving notice to such pharmacist. 
 Warning such pharmacist. 
 Refer the pharmacist to the Disciplinary Council of the Jordan Pharmacist 
Association. 






“Any pharmacist who commits the following violations has to be referred to the 
Association’s Disciplinary Council and shall be punished by the following penalties:- 
           Payment of a fine in the sum of (250 – 500) Dinars in case he, in contravention of the 
provisions of this law, would: 
 In case of publishing and advertising without the consent of both the minster and the 
Association. 
 Display in his pharmacy any expired drugs where the Ministry shall have the right to 
seize those drugs when discovered. 
 Fail to observe the prices determined for any drugs, and any other items priced by the 
Ministry. 
Sell or venture to sell any medical free sample.” 
 
Article 92 
“The Ministry, by a justifying recommendation from the director, may close any public or 
private pharmacy or drugstore wherein a violation had been committed, or he may suspend 
the breaching pharmacist from practicing this profession until such violation has been 




 of August 2008, a new regulation for public health was established and 
implemented.  These new regulations have provided a legal definition for counterfeit 
pharmaceuticals for the first time in the history of the country (JFDA 2008). 
184 
 
The new regulations have emphasised many dimensions that assumed to be effective when 
regulatory authorities enforce them into implementation. These dimensions are as follows:  
 
Article number 31 stated that, the medicine is considered to be counterfeit when: 
The medicine is produced in an unauthorised place or produced in a different company or 
without the permission of the originator company. 
The medicine does not contain an active ingredient or a different level from the active 
ingredient, or another ingredient instead of the active ingredient indicated on the label. 
The medicine has a counterfeit trademark or a counterfeit pedigree papers. 
The production area is different from the real production area on the label. 
 
Article number 32 stated that, it is prohibited and considered to be against the law to deal 
with or to import or to enter any counterfeit medicine to the Kingdom and that includes: 
The free trade zones, the “transit” areas, and borders. It is also prohibited to advertize or to 
publicize any counterfeit medicine. 
 
Article number 33 stated that: 
1- Despite previous legislation, The General Director for Food and Drug Administration 
issues an order that prohibits dealing with any smuggled or counterfeit medicine. 
2- The General Director of Food and Drug Administration (FDA) can delegate any 
specialised employee within the administration or the ministry of health to inspect and 
draw samples from local or imported medicine against a receipt within the rules in order 
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to analyse and test this medicine to assure that it complies with the manufacturer 
standards.  
 
Article number 34   stated that: 
1- If the medicine is found expired or unsuitable for human use after examination of the 
medicine, the Food and Drug Administration must seize the medicine when discovered 
in possession of the pharmacy. 
2- The Court makes a decision to seize the counterfeit or smuggled medicine. 
3- The general director will assign one of the inspector pharmacists to supervise the 
disposal of the counterfeit or the smuggled drug. The new law has also specified certain 
punishments which includes imprisonment or paying fine up to the judge to decide on 
the type of punishment 
 
Article number 65 stated that: 
If the person convicted by buying or selling or exporting counterfeit medicine to the 
kingdom,  he will spend a period not less than 3 years and not more than  5 years in prison 
with hard work, or the convicted individual will pay  a fine not less than JD 1000, and not 
more JD 5000, or both penalties. In some serious circumstance, the fine will be twice as 
much as the price of the confiscated counterfeit drug.                       
The person who convicted of publicizing any counterfeit drug will be jailed for not less 
than one month and not more than 6 months or will pay fine not less than JD 1000 and not 
more than JD 3000 or both penalties. 
 
186 
 
 
 
